WO2006014762A1 - Substituted amide beta secretase inhibitors - Google Patents

Substituted amide beta secretase inhibitors Download PDF

Info

Publication number
WO2006014762A1
WO2006014762A1 PCT/US2005/025780 US2005025780W WO2006014762A1 WO 2006014762 A1 WO2006014762 A1 WO 2006014762A1 US 2005025780 W US2005025780 W US 2005025780W WO 2006014762 A1 WO2006014762 A1 WO 2006014762A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
substituted
aryl
mmol
Prior art date
Application number
PCT/US2005/025780
Other languages
French (fr)
Inventor
Ying Huang
Guoqing Li
Andrew W. Stamford
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to AT05773473T priority Critical patent/ATE491693T1/en
Priority to JP2007522711A priority patent/JP2008507538A/en
Priority to CA002574218A priority patent/CA2574218A1/en
Priority to EP05773473A priority patent/EP1781625B1/en
Priority to MX2007000760A priority patent/MX2007000760A/en
Priority to DE602005025363T priority patent/DE602005025363D1/en
Publication of WO2006014762A1 publication Critical patent/WO2006014762A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to substituted amide beta secretase inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus, plasmepsins, cathepsin D and protozoal enzymes.
  • AD Alzheimer's disease
  • Behavioral changes including confusion, depression and aggression also manifest as the disease progresses.
  • the cognitive and behavioral dysfunction is believed to result from altered neuronal function and neuronal loss in the hippocampus and cerebral cortex.
  • the currently available AD treatments are palliative, and while they ameliorate the cognitive and behavioral disorders, they do not prevent disease progression. Therefore there is an unmet medical need for AD treatments that halt disease progression.
  • AD extracellular ⁇ -amyloid
  • a ⁇ extracellular ⁇ -amyloid
  • intracellular neurofibrillary tangles comprised of abnormally phosphorylated protein tau.
  • Individuals with AD exhibit characteristic A ⁇ deposits, in brain regions known to be important for memory and cognition. It is believed that A ⁇ is the fundamental causative agent of neuronal cell loss and dysfunction which is associated with cognitive and behavioral decline.
  • Amyloid plaques consist predominantly of A ⁇ peptides comprised of 40 - 42 amino acid residues, which are derived from processing of amyloid precursor protein (APP). APP is processed by multiple distinct protease activities.
  • APP amyloid precursor protein
  • a ⁇ peptides result from the cleavage of APP by ⁇ -secretase at the position corresponding to the N-terminus of A ⁇ , and at the C- terminus by ⁇ -secretase activity.
  • APP is also cleaved by ⁇ -secretase activity resulting in the secreted, non-amyloidogenic fragment known as soluble APP.
  • BACE-1 An aspartyl protease known as BACE-1 has been identified as the ⁇ -secretase activity responsible for cleavage of APP at the position corresponding to the N- terminus of A ⁇ peptides.
  • a ⁇ has been shown to be toxic to neuronal cells in vitro and when injected into rodent brains.
  • inherited forms of early-onset AD are known in which well-defined mutations of APP or the presenilins are present.
  • Substituted amine BACE-1 inhibitors are disclosed in, WO 04/04396, WO 02/02505, WO 02/02506, WO 02/02512, WP 02/02518 and WO 02/02520.
  • Renin inhibitors comprising a (1 -amino-2 hydroxy-2-heterocyclic)ethyl moiety are disclosed in WO 89/03842.
  • WO 02/088101 discloses BACE inhibitors functionally described as being comprised of four hydrophobic moieties, as well as series of compounds preferably comprising a heterocyclic or heteroaryl moiety.
  • the present invention relates to compounds having the structural formula I
  • R 2 is hydrogen, alkyl or cycloalkyl
  • R 3 is arylene, heteroarylene, heterocyclylene or cycloalkylene
  • R 4 is hydrogen, -C(O)-alkyl, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, alkoxyalkyl, heterocyclyl, heterocyclylalkyl, heteroaralkyl or heteroaryl;
  • R 5 and R 7 are 1 to 4 moieties, each moiety being independently selected from hydrogen, -OH, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, aralkoxy, heteroaralkoxy and alkoxy, with the proviso that when R 5 and R 7 are -OH, aralkoxy, heteroaralkoxy and alkoxy, R 5 and R 7 are not attached to a ring carbon adjacent to a ring nitrogen;
  • R 9 and R 10 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl, heterocyclylalkyl, alkenyl and alkynyl; or R 9 and R 10 together with the nitrogen to which they are attached, form a 3-7 membered heterocyclyl ring;
  • Y 0 or (H, H); m is O, 1 , 2, or 3; and n is 1 , 2, or 3; wherein each alkyl is optionally substituted with 1 to 3 moieties selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl) 2 , carboxy and -C(O)O-alkyl; and wherein each arylene, heteroarylene, heterocyclylalkyl, heterocyclylene, cycloalkylene, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl, aralkoxy or heteroaralkoxy is optionally substituted with 1 to 4 moieties selected from the group consisting of -CF 3 , alkyl,
  • Compounds represented by formula I are beta-secretase inhibitors useful for the prevention and treatment of Alzheimer's disease.
  • the invention comprises: the method of treating a cardiovascular disease such as hypertension, renal failure, congestive heart failure or another disease modulated by renin inhibition; the method of treating Human Immunodeficiency Virus; the method of treating a cognitive or neurodegenerative disease such as Alzheimer's Disease; the method of inhibiting plasmepsins I and Il for treatment of malaria; the method of inhibiting Cathepsin D for the treatment of Alzheimer's Disease, breast cancer, and ovarian cancer; and the method of inhibiting protozoal enzymes, for example inhibition of Plasmodium falciparnum, for the treatment of fungal infections.
  • Said method of treatment comprise administering at least one compound of formula I to a patient in need of such treatment.
  • the invention comprises the method of treating Alzheimer's Disease comprising administering at least one compound of formula I to a patient in need of such treatment.
  • the invention comprises the method of treating Alzheimer's Disease comprising administering to a patient in need of such treatment a combination of at least one compound of formula I and a cholinesterase inhibitor or a muscarinic mi agonist or m 2 antagonist.
  • the invention relates to a kit comprising in separate containers in a single package pharmaceutical compositions for use in combination, in which one container comprises a compound of formula I in a pharmaceutically acceptable carrier and a second container comprises a cholinesterase inhibitor or a muscarinic Im 1 agonist or m 2 antagonist in a pharmaceutically acceptable carrier, the combined quantities being an effective amount to treat a cognitive disease or neurodegenerative disease such as Alzheimer's Disease.
  • a cognitive disease or neurodegenerative disease such as Alzheimer's Disease.
  • preferred compounds of the invention are those with the following stereochemistry:
  • R 1 can be R 7 wherein n is 2 and R 6 and R 7 are defined herein.
  • R 2 is preferably is alkyl, more preferably methyl .
  • R 3 is arylene or halo-substituted arylene, more preferably phenylene or halo- substituted phenylene, specifically a halo-substituted phenylene, where said halo is preferably fluoride.
  • R 4 is preferably hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, -C(O)Oethyl,
  • R 5 and R 7 independently are alkyl substituted by a cycloalkyl group alkyl or substituted by an aryl or heteroaryl group.
  • R 6 can be aralkyl
  • R 6 is -S(O) 2 -R 8 or more preferably, R 6 is
  • X is a bond connecting R 3 and R 4 , O, alkylene, -alkyl-NHSO 2 - or -alkyl-NHC(O)-;
  • Y is O and n is 2.
  • R 2 is alkyl
  • R 3 is phenylene or halo-substituted phenylene
  • R 4 is hydrogen, -C(O)-alkyl, alkyl, aryl, aralkyl, substituted aryl, substituted aralkyl, alkoxyalkyl, heteroaralkyl, substituted heteroaryl, substituted heteroaralkyl, alkoxyalkyl, heterocyclyl, heterocyclylalkyl, substituted heterocyclyl, substituted heterocyclylalkyl or heteroaryl;
  • R 5 and R 7 are hydrogen, alkyl substituted by a cycloalkyl group, alkyl substituted by an aryl or heteroaryl group;
  • R 6 is aralkyl or -S(O) 2 R 8 ;
  • R 2 is preferably methyl
  • R 4 is preferably hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, -C(O)Oethyl,
  • alkyl means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain.
  • Alkynyl means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain.
  • Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain.
  • Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain.
  • “Lower alkynyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched.
  • Aralkyl or “arylalkyl” means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
  • Alkylaryl means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. Non-limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.
  • Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbornyl, adamantyl and the like, as well as partially saturated species such as, for example, indanyl, tetrahydronaphthyl and the like. Further non- limiting examples of cycloalkyl include the following
  • Ring system substituent may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system.
  • moieties are methylene dioxy, ethylenedioxy, -C(CH 3 ) 2 - and the like which form moieties such as, for example:
  • Heterocyclyl (or heterocycloalkyl) means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 4 to about 7 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system.
  • Preferred heterocyclyls contain about 5 to about 6 ring atoms.
  • the prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom.
  • Any -NH in a heterocyclyl ring may exist protected such as, for example, as an -N(Boc), -N(CBz), - N(Tos) group and the like; such protections are also considered part of this invention.
  • the heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein.
  • the nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S.S-dioxide.
  • Heterocyclylene means a difunctional group obtained by removal of a hydrogen atom from an heterocyclyl group that is defined above.
  • Non-limiting examples of heterocyclylene include piperidylene, pyrrolidinylene, piperazinylene, morpholinylene, thiomorpholinylene, thiazolidinylene, 1 ,4-dioxanylene, tetrahydrofuranylene and tetrahydrothiophenylene.
  • hetero-atom containing ring systems of this invention there are no hydroxyl groups on carbon atoms adjacent to a N, O or S, nor is there an N or S group on a carbon adjacent to another heteroatom.
  • N, O or S there are no hydroxyl groups on carbon atoms adjacent to a N, O or S, nor is there an N or S group on a carbon adjacent to another heteroatom.
  • heteroarylalkyl or heteroaralkyl and “cycloalkylalkyl” mean a heteroaryl- or cycloalkyl- group in which the heteroaryl, cycloalkyl and alkyl are as previously described. Preferred groups contain a lower alkyl group. The bond to the parent moiety is through the alkyl.
  • Heterocyclylalkyl means a heterocyclyl-alkyl group in which the heterocyclyl and the alkyl are as previously described. The bond to the parent moiety is through the alkyl.
  • Preferred hydroxyalkyls contain lower alkyl.
  • suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
  • Aroyl means an aryl-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl.
  • suitable groups include benzoyl and 1- naphthoyl.
  • Alkoxy means an alkyl-O- group in which the alkyl group is as previously described.
  • suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy.
  • the bond to the parent moiety is through the ether oxygen.
  • Alkoxyalkyl means an alkoxy-alkyl group in which the alkoxy and alkyl groups are as previously described.
  • suitable alkoxyalkyl groups include ethoxyethyl, methoxymethyl and ethoxymethyl.
  • the bond to the parent moiety is through the alkyl group.
  • Aryloxy means an aryl-O- group in which the aryl group is as previously described.
  • suitable aryloxy groups include phenoxy and naphthoxy.
  • the bond to the parent moiety is through the ether oxygen.
  • Aralkoxy means an aralkyl-O- group in which the aralkyl group is as previously described.
  • suitable aralkoxy groups include benzyloxy and 1- or 2-naphthalenemethoxy. The bond to the parent moiety is through the ether oxygen.
  • Alkylheteroaryl means an alkyl-heteroaryl group in which the alkyl and heteroaryl groups are as previously described. The bond to the parent moiety is through the heteroaryl.
  • Alkylthio means an alkyl-S- group in which the alkyl group is as previously described.
  • suitable alkylthio groups include methylthio and ethylthio.
  • the bond to the parent moiety is through the sulfur.
  • Arylthio means an aryl-S- group in which the aryl group is as previously described.
  • suitable arylthio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the sulfur.
  • Alkylthio means an aralkyl-S- group in which the aralkyl group is as previously described.
  • Non-limiting example of a suitable aralkylthio group is benzylthio.
  • the bond to the parent moiety is through the sulfur.
  • Alkoxycarbonyl means an alkyl-O-C(O)- group in which the alkyl group is as previously described.
  • suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl.
  • the bond to the parent moiety is through the carbonyl.
  • Aryloxycarbonyl means an aryl-O-C(O)- group in which the aryl group is as previously described.
  • suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl. The bond to the parent moiety is through the carbonyl.
  • Alkoxycarbonyl means an aralkyl-O-C(O)- group in which the aralkyl group is as previously described.
  • a suitable aralkoxycarbonyl group is benzyloxycarbonyl.
  • the bond to the parent moiety is through the carbonyl.
  • Alkylsulfonyl means an alkyl-S(O 2 )- group in which the alkyl group is as previously described. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.
  • Arylsulfonyl means an aryl-S(O 2 )- group in which the aryl group is as previously described. The bond to the parent moiety is through the sulfonyl.
  • Cycloalkylalkyl means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl group is as previously described. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the alkyl.
  • Heteroaralkoxy means a heteroaralkyl-O- group in which the heteroaralkyl group is as previously described. The bond to the parent moiety is through the ether oxygen.
  • Heteroarylsulfonyl means a heteroaryl-S(O 2 )- group in which the heteroaryl group is as previously described. The bond to the parent moiety is through the sulfonyl.
  • Heteroarylthio means a heteroaryl-S- group in which the heteroaryl group is as previously described. The bond to the parent moiety is through the sulfur.
  • substituted means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • stable compound' or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • multicyclic divalent groups for example, arylheterocycloalkylene, can be attached to other groups via bonds that are formed on either ring of said group.
  • arylheterocycloalkylene can be attached to other groups via bonds that are formed on either ring of said group.
  • Substitution on a cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, or heteroarylalkyl moiety includes substitution on the ring portion and/or on the alkyl portion of the group.
  • variables can be the same or different.
  • the wavy line 'vw ⁇ as a b onc j generally indicates a mixture of, or either of, the possible isomers, e.g., containing (R)- and (S)- stereochemistry.
  • the possible isomers e.g., containing (R)- and (S)- stereochemistry.
  • polymorphic forms of the compounds of formula I, and of the salts, solvates and prodrugs of the compounds of formula I, are intended to be included in the present invention.
  • isolated or “in isolated form” for a compound refers to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof.
  • purified or “in purified form” for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.
  • variable e.g., aryl, heterocycle, R 2 , etc.
  • its definition on each occurrence is independent of its definition at every other occurrence.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (Ci-C ⁇ jalkyl, (C 2 - Ci 2 )alkanoyloxymethyl, 1 -(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1- methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1- (alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1- (alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N- (alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-C ⁇ jalkyl, (C 2 - Ci 2 )alkanoyloxymethyl, 1 -(alkanoyloxy)ethyl having from 4 to
  • alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4- crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(Ci-C 2 )alkylamino(C 2 -C 3 )alkyl (such as ⁇ -dimethylaminoethyl), carbamoyl-(Ci-C 2 )alkyl, N,N-di (C r C 2 )alkylcarbamoyl-(C1-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C 2 - C 3 )alkyl, and the like.
  • a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (CrC ⁇ Jalkanoyloxymethyl, 1-((Cr C 6 )alkanoyloxy)ethyl, 1 -methyl-1 -((CrC 6 )alkanoyloxy)ethyl, (C r C 6 )alkoxycarbonyloxymethyl, N-(CrC 6 )alkoxycarbonylaminomethyl, succinoyl, (Ci- C 6 )alkanoyl, ⁇ -amino(Ci-C 4 )alkanyl, arylacyl and ⁇ -aminoacyl, or ⁇ -aminoacyl- ⁇ - aminoacyl, where each ⁇ -aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH) 2 , -P(
  • a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyl, RO-carbonyl, NRR'-carbonyl where R and R' are each independently (CrCio)alkyl, (C 3 -C 7 ) cycloalkyl, benzyl, or R-carbonyl is a natural ⁇ -aminoacyl or natural ⁇ -aminoacyl, — C(OH)C(O)OY 1 wherein Y 1 is H, (Ci-C 6 )alkyl or benzyl, — C(OY 2 )Y 3 wherein Y 2 is (C 1 -C 4 ) alkyl and Y 3 is (C r C 6 )alkyl, carboxy (Ci-C 6 )alkyl, amino(CrC 4 )alkyl or mono-N — or di-
  • Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like.
  • Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, aluminum salts, zinc salts, salts with organic bases (for example, organic amines) such as benzathines, diethylamine, dicyclohexylamines, hydrabamines (formed with N,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D- glucamines, N-methyl-D-glucamides, t-butyl amines, piperazine, phenylcyclohexylamine, choline, tromethamine, and salts with amino acids such as arginine, lysine and the like.
  • organic bases for example, organic amines
  • organic bases for example, organic amines
  • benzathines diethylamine, dicyclohexylamines, hydrabamines (formed with N,N-
  • Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g. decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
  • lower alkyl halides e.g. methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
  • dialkyl sulfates e.g. dimethyl, diethyl, dibutyl, and diamyl sulfates
  • long chain halides
  • Effective amount or “therapeutically effective amount” is meant to describe an amount of compound or a composition of the present invention effective in inhibiting BACE-1 and thus producing the desired therapeutic effect in a suitable patient.
  • a preferred dosage is about 0.001 to 1000 mg/kg of body weight/day of the compound of Formula I or a pharmaceutically acceptable salt or solvate thereof.
  • An especially preferred dosage is about 0.01 to 30 mg/kg of body weight/day of a compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound.
  • This invention is also directed to pharmaceutical compositions for the treatment of neurodegenerative diseases such as Alzheimer's disease which comprise an effective treating amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound and at least one pharmaceutically acceptable carrier.
  • Still yet another aspect of this invention is a method of treating a cognitive or neurodegenerative disease, such as Alzheimer's disease, comprising administering to a mammal in need of such treatment a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound.
  • a further aspect of this invention is a method for treating a cognitive or neurodegenerative disease such as Alzheimer's disease, comprising administering to a mammal a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound.
  • compositions which comprise at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound and at least one pharmaceutically acceptable carrier.
  • This invention is also directed to pharmaceutical compositions for the treatment of neurodegenerative diseases such as Alzheimer's disease which comprise an effective treating amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound and at least one pharmaceutically acceptable carrier.
  • Still yet other aspects of this invention are combinations of a compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound and other compounds as described below. Accordingly, included within the invention is a method for treating neurodegenerative diseases such as Alzheimer's, comprising administering to a mammal (e.g., a female or male human) a. an amount of a first compound, said first compound being a compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound; and b. an amount of a second compound, said second compound being a cholinesterase inhibitor.
  • a mammal e.g., a female or male human
  • anti-inflammatory compounds include but are non limited to non-steroidal anti-inflammatory drugs such as diclofenac (Voltaren, Cataflam), diflunisal (Dolobid), etodolac (Lodine), flurbiprofen (Ansaid), ibuprofen (Motrin, Advil), indomethacin (Indocin), ketoprofen (Orudis, Oruvail), ketorolac
  • non-steroidal anti-inflammatory drugs such as diclofenac (Voltaren, Cataflam), diflunisal (Dolobid), etodolac (Lodine), flurbiprofen (Ansaid), ibuprofen (Motrin, Advil), indomethacin (Indocin), ketoprofen (Orudis, Oruvail), ketorolac
  • HMG-CoA reductase inhibitors for use in combination with compounds of formula I include the "stains," e.g., atorvastatin, lovastatin, simvistatin, pravastatin, fluvastatin and rosuvastatin. Accordingly, included within the invention is a method for treating neurodegenerative diseases such as Alzheimer's, comprising administering to a mammal (e.g., a female or male human) a. an amount of a first compound, said first compound being a compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound; and b. an amount of a second compound, said second compound being a N- methyl-D-aspartate receptor antagonist.
  • a suitable N-methyl-D-aspartate receptor antagonist is, for example, memantine.
  • the pharmaceutical preparation is in a unit dosage form.
  • the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
  • inert, pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
  • the powders and tablets may be comprised of from about 5 to about 95 percent active ingredient.
  • Suitable solid carriers are known in the art, e.g.
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas.
  • a pharmaceutically acceptable carrier such as an inert compressed gas.
  • transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
  • the compound is administered orally.
  • the pharmaceutical preparation is in unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
  • the active components may be co ⁇ administered simultaneously or sequentially, or a single pharmaceutical composition comprising a compound of formula I and one of the other agents in a pharmaceutically acceptable carrier can be administered.
  • the components of the combination can be administered individually or together in any conventional oral or parenteral dosage form such as capsule, tablet, powder, cachet, suspension, solution, suppository, nasal spray, etc.
  • the dosage of the ⁇ -secretase inhibitors other than those of formula I, HMG-CoA reductase inhibitor, gamma-secretase inhibitor, non-steroidal anti-inflammatory agent, N-methyl-D-aspartate receptor antagonist, cholinesterase inhibitor or anti-amyloid antibody can be determined from published material, and may range from 0.001 to 100 mg/kg body weight.
  • the invention also includes multi-agent compositions, kits and methods of treatment, e.g., a compound of formula I can be administed in combination with an HMG-CoA reductase inhibitor and a non-steroidal anti-inflammatory agent
  • a compound of formula I can be administed in combination with an HMG-CoA reductase inhibitor and a non-steroidal anti-inflammatory agent
  • Compounds of Formula I can be produced by processes known to those skilled in the art using either solution phase or solid phase synthesis as shown in the following reaction schemes, in the preparations and examples below, but those skilled in the art will recognize that other procedures can also be suitable.
  • Triphenylphosphine PPh 3
  • Tetrabutylammonium fluoride TBAF Triethylamine: Et 3 N, NEt 3 Or TEA
  • Lithium borohydride LiBH 4
  • BACE-I Cloning, Protein Expression and Purification A predicted soluble form of human BACE1 (sBACEI , corresponding to amino acids 1-454) was generated from the full length BACE1 cDNA (full length human BACE 1 cDNA in pCDNA4/mycHisA construct; University of Toronto) by PCR using the advantage-GC cDNA PCR kit (Clontech, Palo Alto, CA).
  • a Hindlll/Pmel fragment from pCDNA4-sBACE1 myc/His was blunt ended using Klenow and subcloned into the Stu I site of pFASTBACI(A) (Invitrogen).
  • IC 50 determinations for inhibitors were determined by measuring the percent change of the relative fluorescence at 665 nm divided by the relative fluorescence at 620 nm, (665/620 ratio), in the presence of varying concentrations of / and a fixed concentration of enzyme and substrate.
  • Nonlinear regression analysis of this data was performed using GraphPad Prism 3.0 software selecting four parameter logistic equation, that allows for a variable slope.
  • Y Bottom + (Top-Bottom)/ (1 Slope));
  • X is the logarithm of concentration of I
  • Y is the percent change in ratio and Y starts at bottom and goes to top with a sigmoid shape.
  • Compounds of the present invention have an IC 5O range from about 100 to about 10,000 nM, preferably about 100 to about 1000 nM, more preferably about 100 to about 500 nM.
  • Compounds of the preferred stereochemistry have IC 5O values in a range of about 2 to about 500 nM, preferably about 2 to about 100 nM.
  • the compound of the following formula has a IC 50 Of 186 nM.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Disclosed are novel compounds of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4 and X are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering to a patient I need of such treatment a combination of at least one compound of formula (I) and at least one compound selected from the group consisting of β-secretase inhibitors other than those of formula (I), HMG-CoA reductase inhibitors, gamma-secretase inhibitors, non-steroidal anti-inflammatory agents, N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors and anti-amyloid antibodies.

Description

SUBSTITUTED AMIDE BETA SECRETASE INHIBITORS
FIELD OF THE INVENTION
This invention relates to substituted amide beta secretase inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus, plasmepsins, cathepsin D and protozoal enzymes.
BACKGROUND
Alzheimer's disease (AD) is a progressive neurodegenerative disease that is ultimately fatal. Disease progression is associated with gradual loss of cognitive function related to memory, reasoning, orientation and judgment. Behavioral changes including confusion, depression and aggression also manifest as the disease progresses. The cognitive and behavioral dysfunction is believed to result from altered neuronal function and neuronal loss in the hippocampus and cerebral cortex. The currently available AD treatments are palliative, and while they ameliorate the cognitive and behavioral disorders, they do not prevent disease progression. Therefore there is an unmet medical need for AD treatments that halt disease progression.
Pathological hallmarks of AD are the deposition of extracellular β-amyloid (Aβ) plaques and intracellular neurofibrillary tangles comprised of abnormally phosphorylated protein tau. Individuals with AD exhibit characteristic Aβ deposits, in brain regions known to be important for memory and cognition. It is believed that Aβ is the fundamental causative agent of neuronal cell loss and dysfunction which is associated with cognitive and behavioral decline. Amyloid plaques consist predominantly of Aβ peptides comprised of 40 - 42 amino acid residues, which are derived from processing of amyloid precursor protein (APP). APP is processed by multiple distinct protease activities. Aβ peptides result from the cleavage of APP by β-secretase at the position corresponding to the N-terminus of Aβ, and at the C- terminus by γ-secretase activity. APP is also cleaved by α-secretase activity resulting in the secreted, non-amyloidogenic fragment known as soluble APP.
An aspartyl protease known as BACE-1 has been identified as the β-secretase activity responsible for cleavage of APP at the position corresponding to the N- terminus of Aβ peptides.
Accumulated biochemical and genetic evidence supports a central role of Aβ in the etiology of AD. For example, Aβ has been shown to be toxic to neuronal cells in vitro and when injected into rodent brains. Furthermore inherited forms of early-onset AD are known in which well-defined mutations of APP or the presenilins are present.
Substituted amine BACE-1 inhibitors are disclosed in, WO 04/04396, WO 02/02505, WO 02/02506, WO 02/02512, WP 02/02518 and WO 02/02520. Renin inhibitors comprising a (1 -amino-2 hydroxy-2-heterocyclic)ethyl moiety are disclosed in WO 89/03842. WO 02/088101 discloses BACE inhibitors functionally described as being comprised of four hydrophobic moieties, as well as series of compounds preferably comprising a heterocyclic or heteroaryl moiety.
SUMMARY OF THE INVENTION
The present invention relates to compounds having the structural formula I
Figure imgf000003_0001
or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is
Figure imgf000004_0001
R2 is hydrogen, alkyl or cycloalkyl;
R3 is arylene, heteroarylene, heterocyclylene or cycloalkylene;
R4 is hydrogen, -C(O)-alkyl, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, alkoxyalkyl, heterocyclyl, heterocyclylalkyl, heteroaralkyl or heteroaryl;
R5 and R7 are 1 to 4 moieties, each moiety being independently selected from hydrogen, -OH, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, aralkoxy, heteroaralkoxy and alkoxy, with the proviso that when R5 and R7 are -OH, aralkoxy, heteroaralkoxy and alkoxy, R5 and R7 are not attached to a ring carbon adjacent to a ring nitrogen;
R6 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, -C(O)R8, -C(O)OR11, -S(O)R8, -S(O2)R8 or -CN; with the proviso that when Y is =0, R6 cannot be -C(O)R8, -C(O)OR11, -S(O)R8, -S(O2)R8 or -CN; R8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl or -N(R9)(R10);
R9 and R10 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl, heterocyclylalkyl, alkenyl and alkynyl; or R9 and R10 together with the nitrogen to which they are attached, form a 3-7 membered heterocyclyl ring;
R11 is alkyl, cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, alkenyl or alkynyl;
X is a bond connecting R3 and R4, -O-, -S-, alkylene, -alkyleneNH-, -alkyleneNHC(O)-, -alkyleneNHSO2-, -NH-, -NHC(O)-, or -NHSO2-;
Y is =0 or (H, H); m is O, 1 , 2, or 3; and n is 1 , 2, or 3; wherein each alkyl is optionally substituted with 1 to 3 moieties selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl)2, carboxy and -C(O)O-alkyl; and wherein each arylene, heteroarylene, heterocyclylalkyl, heterocyclylene, cycloalkylene, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl, aralkoxy or heteroaralkoxy is optionally substituted with 1 to 4 moieties selected from the group consisting of -CF3, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, arylalkenyl, heteroarylalkenyl, arylalkynyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, -C(=N-CN)-NH2, -C(=NH)-NH2, -C(=NH)-NH(alkyl), YiY2N-, Y^N-alkyl-, Y1Y2NC(O)-, Y1Y2NSO2- and -SO2NYiY2, wherein Y1 and Y2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, -C(O)alkyl and aralkyl, with the proviso that cycloalkyl, cycloalkylene, heterocyclyl and heterocyclylene can be substituted with =O.
Compounds represented by formula I are beta-secretase inhibitors useful for the prevention and treatment of Alzheimer's disease.
In another aspect, the invention relates to a pharmaceutical composition comprising at least one compound of formula I and a pharmaceutically acceptable carrier.
In another aspect, the invention comprises administering at least one compound of formula I to a patient in need of such treatment.
More specifically, the invention comprises: the method of treating a cardiovascular disease such as hypertension, renal failure, congestive heart failure or another disease modulated by renin inhibition; the method of treating Human Immunodeficiency Virus; the method of treating a cognitive or neurodegenerative disease such as Alzheimer's Disease; the method of inhibiting plasmepsins I and Il for treatment of malaria; the method of inhibiting Cathepsin D for the treatment of Alzheimer's Disease, breast cancer, and ovarian cancer; and the method of inhibiting protozoal enzymes, for example inhibition of Plasmodium falciparnum, for the treatment of fungal infections. Said method of treatment comprise administering at least one compound of formula I to a patient in need of such treatment. In particular, the invention comprises the method of treating Alzheimer's Disease comprising administering at least one compound of formula I to a patient in need of such treatment.
In another aspect, the invention comprises the method of treating Alzheimer's Disease comprising administering to a patient in need of such treatment a combination of at least one compound of formula I and a cholinesterase inhibitor or a muscarinic mi agonist or m2 antagonist.
In a final aspect, the invention relates to a kit comprising in separate containers in a single package pharmaceutical compositions for use in combination, in which one container comprises a compound of formula I in a pharmaceutically acceptable carrier and a second container comprises a cholinesterase inhibitor or a muscarinic Im1 agonist or m2 antagonist in a pharmaceutically acceptable carrier, the combined quantities being an effective amount to treat a cognitive disease or neurodegenerative disease such as Alzheimer's Disease. DETAILED DESCRIPTION:
Referring to formula I, above, preferred compounds of the invention are those with the following stereochemistry:
Figure imgf000006_0001
Figure imgf000006_0002
In preferred compounds of formula I, R1 can be R7 wherein n is 2 and R6 and R7 are defined herein. R2 is preferably is alkyl, more preferably methyl .
R3 is arylene or halo-substituted arylene, more preferably phenylene or halo- substituted phenylene, specifically a halo-substituted phenylene, where said halo is preferably fluoride.
R4 is hydrogen, -C(O)-alkyl, alkyl, aryl, aralkyl, substituted aryl, substituted aralkyl, alkoxyalkyl, heteroaralkyl, substituted heteroaryl, substituted heteroaralkyl, alkoxyalkyl, heterocyclyl, heterocyclylalkyl, substituted heterocyclyl, substituted heterocyclylalkyl or heteroaryl.
Or in the alternative, R4 is preferably hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, -C(O)Oethyl,
Figure imgf000007_0001
Figure imgf000008_0001
Preferably, R5 and R7 independently are alkyl substituted by a cycloalkyl group alkyl or substituted by an aryl or heteroaryl group.
In a preferred embodiment of the compounds of formula I, R6 can be aralkyl,
preferably
Figure imgf000008_0002
Or in the alternative R6 is -S(O)2-R8 or more preferably, R6 is
Figure imgf000009_0001
Preferably X is a bond connecting R3 and R4, O, alkylene, -alkyl-NHSO2- or -alkyl-NHC(O)-; Y is O and n is 2.
In a particular preferred embodiment of the compound of formula I,
Figure imgf000009_0002
R2 is alkyl;
R3 is phenylene or halo-substituted phenylene;
R4 is hydrogen, -C(O)-alkyl, alkyl, aryl, aralkyl, substituted aryl, substituted aralkyl, alkoxyalkyl, heteroaralkyl, substituted heteroaryl, substituted heteroaralkyl, alkoxyalkyl, heterocyclyl, heterocyclylalkyl, substituted heterocyclyl, substituted heterocyclylalkyl or heteroaryl;
R5 and R7 are hydrogen, alkyl substituted by a cycloalkyl group, alkyl substituted by an aryl or heteroaryl group;
R6 is aralkyl or -S(O)2R8;
Figure imgf000009_0003
X is a bond connecting R3 and R4, O, alkylene, -alkyl-NHSO2- or -alkyl-NHC(O)-; and
Y is O.
In the above-preferred embodiment, R2 is preferably methyl;
R3 preferably is
Figure imgf000010_0001
R4 is preferably hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, -C(O)Oethyl,
Figure imgf000010_0002
Figure imgf000011_0001
R7 is preferably hydrogen; and preferably X is a bond connecting R* and R4, O, alkylenyl, -alkyl-NHSO2- or -alkyl-NHC(O)-; Y is O and n is 2.
It is noted that the carbons of formula I may be replaced with 1 to 3 silicon atoms so long as all valency requirements are satisfied.
Except where stated otherwise, the following definitions apply throughout the present specification and claims. These definitions apply regardless of whether a term is used by itself or in combination with other terms. Hence the definition of
"alkyl" applies to "alkyl" as well as to the "alkyl" portions of "alkoxy", "cycloalkyl" and so forth.
As used above, and throughout the specification, the following terms, unless otherwise indicated, shall be understood to have the following meanings: "Patient" includes both human and animals. "Mammal" means humans and other mammalian animals. "Alkyl" means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. "Lower alkyl" means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched. Non-limiting examples of suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n- pentyl, heptyl, nonyl and decyl. Substituted alkyl groups include but are not limited to fluoromethyl, trifluoromethyl and cyclopropylmethyl .
"Alkylene" means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above. Non-limiting examples of alkylene include methylene and ethylene.
"Alkenyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain. "Lower alkenyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. The term "substituted alkenyl" means that the alkenyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl. aryl, cycloalkyl, cyano, alkoxy and -S(alkyl). Non-limiting examples of suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl.
"Alkynyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain. "Lower alkynyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl. The term "substituted alkynyl" means that the alkynyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl, 3-methylbutynyl, n-pentynyl, and decynyl.
"Aryl" means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein, or two substituents on
adjacent carbons can be linked together to form - ?js - ' ϊ s 'd O or
Figure imgf000013_0001
Non- limiting examples of suitable aryl groups include phenyl and naphthyl.
"Arylene" means a difunctional group obtained by removal of a hydrogen atom from an aryl group that is defined above. Non-limiting examples of arylene include phenylene and naphthylene.
"Heteroaryl" means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. Preferred heteroaryls contain about 5 to about 6 ring atoms. The "heteroaryl" can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom. A nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N- oxide. Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1 ,2,4- thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1 ,2- a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1 ,2,4-triazinyl, benzothiazolyl and the like. The term "heteroaryl" also refers to partially saturated heteroaryl moieties such as, for example, tetrahydroisoquinolyl, tetrahydroquinolyl and the like. "Heteroarylene" means a difunctional group obtained by removal of a hydrogen atom from a heteroaryl group that is defined above. Non-limiting examples of pyridylene, pyrazinylene, furanylene, thienylene and pyrimidinylene.
"Aralkyl" or "arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
"Alkylaryl" means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. Non-limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.
"Cycloalkyl" means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7 ring atoms. The cycloalkyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbornyl, adamantyl and the like, as well as partially saturated species such as, for example, indanyl, tetrahydronaphthyl and the like. Further non- limiting examples of cycloalkyl include the following
"Cycloalkylene" means a difunctional group obtained by removal of a hydrogen atom from a cycloalkyl group that is defined above. Non-limiting examples of cycloalkylene include cyclobutylene and cyclopropylene.
"Halo" means fluoro, chloro, bromo or iodo. Preferred are fluoro, chloro and bromo.
"Ring system substituent" means a substituent attached to an aromatic or non- aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of -CF3, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, heteroarylalkenyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio, hetθroaralkylthio, cycloalkyl, heterocyclyl, =0, -C(=N-CN)-NH2) -C(=NH)-NH2) -C(=NH)-NH(alkyl), YiY2N-, Y^N-alkyl-, Y1Y2NC(O)-, YiY2NSO2- and -SO2NYiY2, wherein Y1 and Y2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, and aralkyl. "Ring system substituent" may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system. Examples of such moieties are methylene dioxy, ethylenedioxy, -C(CH3)2- and the like which form moieties such as, for example:
Figure imgf000016_0001
"Heterocyclyl" (or heterocycloalkyl) means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 4 to about 7 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. Any -NH in a heterocyclyl ring may exist protected such as, for example, as an -N(Boc), -N(CBz), - N(Tos) group and the like; such protections are also considered part of this invention. The heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S.S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1 ,3-dioxolanyl, 1 ,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.
"Heterocyclylene" means a difunctional group obtained by removal of a hydrogen atom from an heterocyclyl group that is defined above. Non-limiting examples of heterocyclylene include piperidylene, pyrrolidinylene, piperazinylene, morpholinylene, thiomorpholinylene, thiazolidinylene, 1 ,4-dioxanylene, tetrahydrofuranylene and tetrahydrothiophenylene.
It should be noted that in hetero-atom containing ring systems of this invention, there are no hydroxyl groups on carbon atoms adjacent to a N, O or S, nor is there an N or S group on a carbon adjacent to another heteroatom. Thus, for example, in the ring:
Figure imgf000017_0001
there is no -OH attached directly to carbons marked 2 and 5. Those skilled in the art will recognize that certain compounds of formula I are tautomeric, and all such tautomeric forms are contemplated herein as part of the present invention. For example, the moieties:
Figure imgf000017_0002
are considered equivalent in certain embodiments of this invention. Similarly, "heteroarylalkyl or heteroaralkyl" and "cycloalkylalkyl" mean a heteroaryl- or cycloalkyl- group in which the heteroaryl, cycloalkyl and alkyl are as previously described. Preferred groups contain a lower alkyl group. The bond to the parent moiety is through the alkyl.
"Arylalkenyl" means a group derived from aryl and alkenyl as defined herein. Preferred arylalkenyls are those wherein aryl is phenyl and the alkenyl consists of about 3 to about 6 atoms. The arylalkenyl can be optionally substituted by one or more ring system substituents. The bond to the parent moiety is through a non- aromatic carbon atom.
"Arylalkynyl" means a group derived from aryl and alkynyl as defined herein. Preferred arylalkynyls are those wherein aryl is phenyl and the alkynyl consists of about 3 to about 6 atoms. The arylalkynyl can be optionally substituted by one or more ring system substituents. The bond to the parent moiety is through a non- aromatic carbon atom. "Alkynylalkyl" means an alkynyl-alkyl- group in which the alkynyl and alkyl are as previously described. Preferred alkynylalkyls contain a lower alkynyl and a lower alkyl group. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable alkynylalkyl groups include propargylmethyl. "Heteroaralkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group. Non-limiting examples of suitable heteroaralkyl groups include pyridylmethyl, and quinolin-3-ylmethyl. The bond to the parent moiety is through the alkyl.
"Heteroaralkylthio" means a heteroaralkyl-S- group in which the heteroaralkyl is as previously described. Preferred heteroaralkylthios contain a lower alkyl group. The bond to the parent moiety is through the sulfur.
"Heteroarylalkenyl" means a heteroaryl-alkenyl group in which the heteroaryl and the alkenyl are as previously described. Preferred heteroarylalkenyls contain a lower alkenyl group. The bond to the parent moiety is through the alkenyl. "Heteroarylalkynyl" means a heteroaryl-alkynyl group in which the heteroaryl and the alkynyl are as previously described. Preferred heteroarylalkynyls contain a lower alkynyl group. The bond to the parent moiety is through the alkynyl.
"Heterocyclylalkyl" means a heterocyclyl-alkyl group in which the heterocyclyl and the alkyl are as previously described. The bond to the parent moiety is through the alkyl.
"Hydroxyalkyl" means a HO-alkyl- group in which alkyl is as previously defined.
Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
"Acyl" means an H-C(O)-, alkyl-C(O)- or cycloalkyl-C(O)-, group in which the various groups are as previously described. The bond to the parent moiety is through the carbonyl. Preferred acyls contain a lower alkyl. Non-limiting examples of suitable acyl groups include formyl, acetyl, propanoyl, 2-methylpropanoyl, butanoyl and cyclohexanoyl.
"Aroyl" means an aryl-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl. Non-limiting examples of suitable groups include benzoyl and 1- naphthoyl.
"Alkoxy" means an alkyl-O- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parent moiety is through the ether oxygen.
"Alkoxyalkyl" means an alkoxy-alkyl group in which the alkoxy and alkyl groups are as previously described. Non-limiting examples of suitable alkoxyalkyl groups include ethoxyethyl, methoxymethyl and ethoxymethyl. The bond to the parent moiety is through the alkyl group.
"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen. "Aralkoxy" means an aralkyl-O- group in which the aralkyl group is as previously described. Non-limiting examples of suitable aralkoxy groups include benzyloxy and 1- or 2-naphthalenemethoxy. The bond to the parent moiety is through the ether oxygen.
"Alkylheteroaryl" means an alkyl-heteroaryl group in which the alkyl and heteroaryl groups are as previously described. The bond to the parent moiety is through the heteroaryl.
"Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkylthio groups include methylthio and ethylthio. The bond to the parent moiety is through the sulfur. "Arylthio" means an aryl-S- group in which the aryl group is as previously described. Non-limiting examples of suitable arylthio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the sulfur.
"Aralkylthio" means an aralkyl-S- group in which the aralkyl group is as previously described. Non-limiting example of a suitable aralkylthio group is benzylthio. The bond to the parent moiety is through the sulfur.
"Alkoxycarbonyl" means an alkyl-O-C(O)- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyl. "Aryloxycarbonyl" means an aryl-O-C(O)- group in which the aryl group is as previously described. Non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl. The bond to the parent moiety is through the carbonyl. "Aralkoxycarbonyl" means an aralkyl-O-C(O)- group in which the aralkyl group is as previously described. Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl. The bond to the parent moiety is through the carbonyl.
"Alkylsulfonyl" means an alkyl-S(O2)- group in which the alkyl group is as previously described. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.
"Arylsulfonyl" means an aryl-S(O2)- group in which the aryl group is as previously described. The bond to the parent moiety is through the sulfonyl.
"Cycloalkylalkyl" means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl group is as previously described. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the alkyl.
"Heteroaralkoxy" means a heteroaralkyl-O- group in which the heteroaralkyl group is as previously described. The bond to the parent moiety is through the ether oxygen. "Heteroarylsulfonyl" means a heteroaryl-S(O2)- group in which the heteroaryl group is as previously described. The bond to the parent moiety is through the sulfonyl.
"Heteroarylthio" means a heteroaryl-S- group in which the heteroaryl group is as previously described. The bond to the parent moiety is through the sulfur. The term "substituted" means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By "stable compound' or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
The suffix "ene" on alkyl, aryl, hetercycloalkyl, etc. indicates a divalent moiety,
e.g., -CH2CH2- is ethylene, and ^~^_y~^ is para-phenylene. It is understood that multicyclic divalent groups, for example, arylheterocycloalkylene, can be attached to other groups via bonds that are formed on either ring of said group. For example,
Figure imgf000021_0001
The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties, in available position or positions.
Substitution on a cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, or heteroarylalkyl moiety includes substitution on the ring portion and/or on the alkyl portion of the group.
When a variable appears more than once in a group, e.g., R8 in -N(R8)2, or a variable appears more than once in the structure of formula I, e.g., R15 may appear in both R1 and R3, the variables can be the same or different.
With reference to the number of moieties (e.g., substituents, groups or rings) in a compound, unless otherwise defined, the phrases "one or more" and "at least one" mean that there can be as many moieties as chemically permitted, and the determination of the maximum number of such moieties is well within the knowledge of those skilled in the art. With respect to the compositions and methods comprising the use of "at least one compound of formula I," one to three compounds of formula I can be administered at the same time, preferably one.
The wavy line 'vwυ as a boncj generally indicates a mixture of, or either of, the possible isomers, e.g., containing (R)- and (S)- stereochemistry. For example,
means containing both and
Figure imgf000021_0004
Figure imgf000021_0002
Figure imgf000021_0003
Lines drawn into the ring systems, such as, for example:
Figure imgf000021_0005
indicate that the indicated line (bond) may be attached to any of the substitutable ring carbon atoms.
As well known in the art, a bond drawn from a particular atom wherein no moiety is depicted at the terminal end of the bond indicates a methyl group bound through that bond to the atom, unless stated otherwise. For example: represents
Figure imgf000022_0002
Figure imgf000022_0001
Polymorphic forms of the compounds of formula I, and of the salts, solvates and prodrugs of the compounds of formula I, are intended to be included in the present invention. The term "isolated" or "in isolated form" for a compound refers to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof. The term "purified" or "in purified form" for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.
It should also be noted that any heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the hydrogen atom(s) to satisfy the valences. When a functional group in a compound is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in organic Synthesis (1991 ), Wiley, New York.
When any variable (e.g., aryl, heterocycle, R2, etc.) occurs more than one time in any constituent or in Formula I, its definition on each occurrence is independent of its definition at every other occurrence.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
Prodrugs and solvates of the compounds of the invention are also contemplated herein. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term "prodrug" means a compound (e.g, a drug precursor) that is transformed in vivo to yield a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro¬ drugs as Novel Delivery Systems," Vol. 14 of the A. C. S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
For example, if a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (Ci-Cβjalkyl, (C2- Ci2)alkanoyloxymethyl, 1 -(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1- methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1- (alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1- (alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N- (alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-
(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4- crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(Ci-C2)alkylamino(C2-C3)alkyl (such as β-dimethylaminoethyl), carbamoyl-(Ci-C2)alkyl, N,N-di (Cr C2)alkylcarbamoyl-(C1-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2- C3)alkyl, and the like.
Similarly, if a compound of Formula (I) contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (CrCβJalkanoyloxymethyl, 1-((Cr C6)alkanoyloxy)ethyl, 1 -methyl-1 -((CrC6)alkanoyloxy)ethyl, (Cr C6)alkoxycarbonyloxymethyl, N-(CrC6)alkoxycarbonylaminomethyl, succinoyl, (Ci- C6)alkanoyl, α-amino(Ci-C4)alkanyl, arylacyl and α-aminoacyl, or α-aminoacyl-α- aminoacyl, where each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, -P(O)(O(CrC6)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate), and the like.
If a compound of Formula (I) incorporates an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyl, RO-carbonyl, NRR'-carbonyl where R and R' are each independently (CrCio)alkyl, (C3-C7) cycloalkyl, benzyl, or R-carbonyl is a natural α-aminoacyl or natural α-aminoacyl, — C(OH)C(O)OY1 wherein Y1 is H, (Ci-C6)alkyl or benzyl, — C(OY2)Y3 wherein Y2 is (C1-C4) alkyl and Y3 is (CrC6)alkyl, carboxy (Ci-C6)alkyl, amino(CrC4)alkyl or mono-N — or di-N,N-(Ci-C6)alkylaminoalkyl, -C(Y4) Y5 wherein Y4 is H or methyl and Y5 is mono-N— or di-N,N-(Ci-C6)alkylamino morpholino, piperidin-1-yl or pyrrolidin-1-yl, and the like.
"Solvate" means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate" is a solvate wherein the solvent molecule is H2O. The compounds of formula I form salts which are also within the scope of this invention. Reference to a compound of formula I herein is understood to include reference to salts thereof, unless otherwise indicated. The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of formula I contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the formula I may be formed, for example, by reacting a compound of formula I with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization. Acids (and bases) which are generally considered suitable for the formation of pharmaceutically useful salts from basic (or acidic) pharmaceutical compounds are discussed, for example, by S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1 ) 1 -19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; in The Orange Book (Food & Drug Administration, Washington, D. C. on their website); and P. Heinrich Stahl, Camille G. Wermuth (Eds.), Handbook of Pharmaceutical Salts: Properties, Selection, and Use, (2002) Int'l. Union of Pure and Applied Chemistry, pp. 330-331. These disclosures are incorporated herein by reference thereto.
Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.
Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, aluminum salts, zinc salts, salts with organic bases (for example, organic amines) such as benzathines, diethylamine, dicyclohexylamines, hydrabamines (formed with N,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D- glucamines, N-methyl-D-glucamides, t-butyl amines, piperazine, phenylcyclohexylamine, choline, tromethamine, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g. decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
Compounds of Formula I1 and salts, solvates and prodrugs thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention. All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates and prodrugs of the compounds as well as the salts and solvates of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations. The use of the terms "salt", "solvate" "prodrug" and the like, is intended to equally apply to the salt, solvate and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds. Compounds represented by formula I can be beta-secretase inhibitors useful for the prevention and treatment of Alzheimer's disease.
An aspect of this invention is a method of treating a mammal (e.g., human) having a disease or condition mediated or exacerbated by BACE-1 (an aspartyl protease) by administering a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound to the mammal.
"Effective amount" or "therapeutically effective amount" is meant to describe an amount of compound or a composition of the present invention effective in inhibiting BACE-1 and thus producing the desired therapeutic effect in a suitable patient.
A preferred dosage is about 0.001 to 1000 mg/kg of body weight/day of the compound of Formula I or a pharmaceutically acceptable salt or solvate thereof. An especially preferred dosage is about 0.01 to 30 mg/kg of body weight/day of a compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound.
Still yet another aspect of this invention is a method of treating a cognitive or neurodegenerative disease, such as Alzheimer's disease, comprising administering to a mammal in need of such treatment a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound.
A further aspect of this invention is a method for treating a cognitive or neurodegenerative disease such as Alzheimer's disease, comprising administering to a mammal a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound.
This invention is also directed to pharmaceutical compositions, which comprise at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound and at least one pharmaceutically acceptable carrier.
This invention is also directed to pharmaceutical compositions for the treatment of neurodegenerative diseases such as Alzheimer's disease which comprise an effective treating amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound and at least one pharmaceutically acceptable carrier.
A preferred dosage is about 0.001 to 1000 mg/kg of body weight/day of the compound of Formula I or a pharmaceutically acceptable salt or solvate thereof. An especially preferred dosage is about 0.01 to 30 mg/kg of body weight/day of a compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound.
Still yet another aspect of this invention is a method of treating a cognitive or neurodegenerative disease, such as Alzheimer's disease, comprising administering to a mammal in need of such treatment a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound.
A further aspect of this invention is a method for treating a cognitive or neurodegenerative disease such as Alzheimer's disease, comprising administering to a mammal a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound.
This invention is also directed to pharmaceutical compositions, which comprise at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound and at least one pharmaceutically acceptable carrier.
This invention is also directed to pharmaceutical compositions for the treatment of neurodegenerative diseases such as Alzheimer's disease which comprise an effective treating amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound and at least one pharmaceutically acceptable carrier.
For the combination aspect, the use of any β-secretase inhibitor other than those of formula I is contemplated; β-secretase inhibitory activity can be determined by the procedures described below. Useful β-secretase inhibitors are those disclosed in, but are not limited to, WO 02/02505, WO 02/02506, WO 02/02512, WP 02/02518, WO 02/02520 and WO 02/088101.
Still yet other aspects of this invention are combinations of a compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound and other compounds as described below. Accordingly, included within the invention is a method for treating neurodegenerative diseases such as Alzheimer's, comprising administering to a mammal (e.g., a female or male human) a. an amount of a first compound, said first compound being a compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound; and b. an amount of a second compound, said second compound being a cholinesterase inhibitor.
Cholinesterase inhibitors for use in the combination include acetyl- and/or butyrylchlolinesterase inhibitors. Examples of cholinesterase inhibitors include tacrine, donepezil, rivastigmine, galantamine, pyridostigmine and neostigmine. Accordingly, included within the invention is a method for treating neurodegenerative diseases such as Alzheimer's, comprising administering to a mammal (e.g., a female or male human) a. an amount of a first compound, said first compound being a compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound; and b. an amount of a second compound, said second compound being an anti-amyloid antibody. Anti amyloid antibodies are described, for example, in Hock et al, Nature Medicine, 8 (2002), p. 1270-1275.
Accordingly, included within the invention is a method for treating neurodegenerative diseases such as Alzheimer's, comprising administering to a mammal (e.g., a female or male human) a. an amount of a first compound, said first compound being a compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound; and b. an amount of a second compound, said second compound being an anti-inflammatory compound. Examples of anti-inflammatory compounds include but are non limited to non-steroidal anti-inflammatory drugs such as diclofenac (Voltaren, Cataflam), diflunisal (Dolobid), etodolac (Lodine), flurbiprofen (Ansaid), ibuprofen (Motrin, Advil), indomethacin (Indocin), ketoprofen (Orudis, Oruvail), ketorolac
(Toradol), nabumetone (Relafen), naproxen (Naprosyn, Alleve), oxaprozin (Daypro), piroxicam (Feldene), sulindac (Clinoril), tolmetin (Tolectin), celecoxib (Celebrex) and rofecoxib (Vioxx).
Accordingly, included within the invention is a method for treating neurodegenerative diseases such as Alzheimer's, comprising administering to a mammal (e.g., a female or male human) a. an amount of a first compound, said first compound being a compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound; and b. an amount of a second compound, said second compound being a gamma secretase inhibitor. Gamma-secretase inhibitors for use in the combination of this invention can be determined by procedures known in the art. Typical gamma- secretase inhibitors include, but are not limited to, those described in WO 03/013527, US 6,683,091 , WO 03/066592, USSN 10/663,042, filed September 16, 2003, WO 00/247671 , WO 00/050391 , WO 00/007995 and WO 03/018543. Accordingly, included within the invention is a method for treating neurodegenerative diseases such as Alzheimer's, comprising administering to a mammal (e.g., a female or male human) a. an amount of a first compound, said first compound being a compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound; and b. an amount of a second compound, said second compound being a HMG-CoA reductase inhibitor compound. HMG-CoA reductase inhibitors for use in combination with compounds of formula I include the "stains," e.g., atorvastatin, lovastatin, simvistatin, pravastatin, fluvastatin and rosuvastatin. Accordingly, included within the invention is a method for treating neurodegenerative diseases such as Alzheimer's, comprising administering to a mammal (e.g., a female or male human) a. an amount of a first compound, said first compound being a compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound; and b. an amount of a second compound, said second compound being a N- methyl-D-aspartate receptor antagonist. A suitable N-methyl-D-aspartate receptor antagonist is, for example, memantine.
Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 1000 mg, preferably from about 1 mg to about 50 mg, more preferably from about 1 mg to about 25 mg, according to the particular application.
The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
The amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 300 mg/day, preferably 1 rng/day to 50 mg/day, in two to four divided doses.
The amount and frequency of administration of the compounds of the combinations (beta secreatse inhibitors other than those of formula I, NSAIDS, statin drugs, cholinesterase inhibitors, etc.), and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.
For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify. Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection. Liquid form preparations may also include solutions for intranasal administration.
Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions. The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
Preferably the compound is administered orally. Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose. When a compound of formula I is used in combination with a β-secretase inhibitors other than those of formula I, an HMG-CoA reductase inhibitor, a gamma- secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody to treat a cognitive disorder or neurodegenerative disorder, the active components may be co¬ administered simultaneously or sequentially, or a single pharmaceutical composition comprising a compound of formula I and one of the other agents in a pharmaceutically acceptable carrier can be administered. The components of the combination can be administered individually or together in any conventional oral or parenteral dosage form such as capsule, tablet, powder, cachet, suspension, solution, suppository, nasal spray, etc. The dosage of the β-secretase inhibitors other than those of formula I, HMG-CoA reductase inhibitor, gamma-secretase inhibitor, non-steroidal anti-inflammatory agent, N-methyl-D-aspartate receptor antagonist, cholinesterase inhibitor or anti-amyloid antibody can be determined from published material, and may range from 0.001 to 100 mg/kg body weight.
When separate pharmaceutical compositions of a compound of formula I and a β-secretase inhibitors other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D- aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody are to be administered, they can be provided in a kit comprising in a single package, one container comprising a compound of formula I in a pharmaceutically acceptable carrier, and a separate container comprising the other agent in a pharmaceutically acceptable carrier, with the compound of formula I and the other agent being present in amounts such that the combination is therapeutically effective. A kit is advantageous for administering a combination when, for example, the components must be administered at different time intervals or when they are in different dosage forms.
The invention also includes multi-agent compositions, kits and methods of treatment, e.g., a compound of formula I can be administed in combination with an HMG-CoA reductase inhibitor and a non-steroidal anti-inflammatory agent Compounds of Formula I can be produced by processes known to those skilled in the art using either solution phase or solid phase synthesis as shown in the following reaction schemes, in the preparations and examples below, but those skilled in the art will recognize that other procedures can also be suitable.
In the Schemes and in the Examples below, the following abbreviations are used: methyl: Me; ethyl: Et; propyl: Pr; butyl: Bu; benzyl: Bn ethyl acetate: EtOAc benzyloxycarbonyl: Cbz
N,N-dimethylformamide: DMF:
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride: EDC or EDCI room temperature: RT hour: h minute: min retention time: tR trifluoroacetic acid: TFA tetrahydrofuran: THF
1-hydroxybenzotriazole: HOBt methanol: MeOH ethanol: EtOH diethyl ether: Et2O acetic acid: AcOH dimethylsulfoxide: DMSO lithium diisopropylamide: LDA terf-dimethylsilyl chloride: TBSCI te/t-dimethylsilyl: TBS triphenyl phosphine: PPh3 diisopropyl azodicarboxylate: DIAD copper(l) bromide-dimethyl sulfide: CuBr-Me2S tertiary butyloxycarbonyl: Boc
Palladium tetrakis (Triphenylphosphine): Pd(PPh3J4
Triphenylphosphine: PPh3
Tetrabutylammonium fluoride: TBAF Triethylamine: Et3N, NEt3 Or TEA
Lithium borohydride: LiBH4
(trimethylsilyl) diazomethane: TMSCHN2 benzyl bromide: BnBr Lithium aluminum hydride: LAH or LiAIH4
Di-terf-butyl dicarbonate: (Boc)2O
4-dimethylaminopyridine: DMAP butyllithium: BuLi
Benzyl chloride: BnCI oxalyl chloride: (COCI)2
Palladium diphenylphosphinoferrocene chloride: Pd(dppf)CI2
Preparative thin layer chromatography: PTLC high pressure liquid chromatography: HPLC liquid chromatography mass spectrometry: LCMS thin layer chromatography: TLC
Boron trifluoride diethyl etherate: BF3-Et2O
Triethylsilane: Et3SiH
N, N diisopropylethylamine: DIEA
Diisopropylamine: DIPA Acetic anhydride: Ac2O dimethylacetamide: DMA
GENERALSCHEMES: General Scheme 1
Figure imgf000035_0001
General Scheme 2
Figure imgf000035_0002
General Scheme 3
Figure imgf000035_0003
c
Figure imgf000036_0001
General Scheme 4
Figure imgf000036_0002
General Scheme 5
Figure imgf000036_0003
Ac2O TFA
Figure imgf000036_0004
Figure imgf000036_0005
Figure imgf000037_0001
To an ice-cold solution of Boc-L-3-bromophenylalanine (9.44 g, 27.4 mmol) in toluene (60 ml) and MeOH (12 ml) was added 2M (trimethylsilyl) diazomethane in hexanes (20 ml). The solution was stirred at RT for 1 h and AcOH (2 ml) was added. The mixture was concentrated and the residue was dissolved in 20% MeOH/CH2CI2 (40 ml). The solution was cooled in an ice-water bath and 4N HCI/dioxane (36 ml) was added via dropping funnel over 30 min. After the addition was complete, the mixture was warmed to RT and stirred for 4 h. The mixture was concentrated to give the product (8.95 g, 100%). MS m/e 258 (M+H)+
Figure imgf000037_0002
To a solution of the product of Step 1 (8.95 g, 27.4 mmol) in THF (80 ml) and
DMSO (20 ml) were added sodium bicarbonate (14.6 g, 174 mmol) and benzyl bromide (15.9 g, 91.4 mmol). The mixture was stirred at 800C for 24 h. The mixture was cooled to RT and water (120 ml) and EtOAc (100 ml) were added. The aqueous layer was extracted with EtOAc (2x100 ml) and the combined organic layer was washed with saturated sodium bicarbonate (100 ml), dried (MgSO4), concentrated, and purified by column chromatography (gradient EtOAc/Hexanes 0-5%) to give the product (10.4 g, 87%). MS m/e 438 (M+H)+
Figure imgf000038_0001
To an ice-cold solution of the product of Step 2 (10.4 g, 23.8 mmol) in THF (100 ml) was added LAH (1.42 g, 37.4 mmol) in several portions. After the addition was complete, the mixture was warmed to RT and stirred for 4.5 h. The reaction was quenched with slow addition of water (5 ml), 1 N NaOH (10 ml), and water (5 ml). The mixture was stirred until the grey color disappeared then filtered. The filtrate was concentrated and the residue was partitioned between CH2CI2 (100 ml) and brine. The organic layer was dried (MgSO4), concentrated, and purified by column chromatography (gradient EtOAc/Hexanes 0-10%) to give the product (5.70 g, 58%). MS m/e 410 (M+H)+
Figure imgf000038_0002
To a solution of piperazinone (10.0 g, 100 mmol), triethylamine (20.2 g, 200 mmol), and DMAP (50 mg) in CH2CI2 (250 ml) in an ice-water bath was added
(BoC)2O (22.9 g, 105 mmol) slowly. The mixture was stirred in the ice-water bath for 1 h and at RT for 4.5 h. The mixture was diluted with CH2CI2 (250 ml), washed with water (200 ml), 5% citric acid (200 ml), 1 N HCI (200 ml), saturated sodium bicarbonate (20 ml) and brine. The organic layer was dried (MgSO4) and concentrated to give the product (18.0 g, 90%). MS m/e 201 (M+H)+
Figure imgf000038_0003
To a solution of the product of Step 4 (10.0 g, 50.0 mmol) in anhydrous DMF (250 ml) in an ice-water bath were added sodium hydride (2.40 g, 60.0 mmol) and benzyl chloride (6.60 g, 52.5 mmol). The mixture was stirred at RT for 4.5 h. The reaction was quenched with water (10 ml), diluted with CH2CI2 (500 ml), and washed with water (2x250ml). The organic layer was extracted with saturated NH4CI (200 ml), dried (MgSO4), concentrated, and purified by column chromatography (gradient MeOH/CH2CI2 0-5%) to give the product (10.7 g, 74%). 1H-NMR (CDCI3): 5=7.2-7.3 (m, 5H)1 4.57 (s, 2H), 4.10 (s, 2H), 3.53 (m, 2H), 3.19 (m, 2H), 1.41 (s, 9H).
Figure imgf000039_0001
To a solution of oxalyl chloride (1.08 g, 8.30 mmol) in CH2CI2 (7 ml) in a dry ice-acetone bath was added DMSO (1.14 g, 14.6 mmol). After 5 min, a solution of the product of Step 3 (3.01 g, 7.34 mmol) in CH2CI2 (7 ml) was added and the mixture was stirred for 1 h. Diisopropylethylamine (3.28 g, 25.4 mmol) was added and after 2 min the cooling bath was removed. The mixture was stirred for 30 min and diluted with water (50 ml). CH2CI2 (40 ml) was added and the aqueous layer was extracted with CH2CI2 (40 ml). The combined organic layer was washed with brine, dried (MgSO4), and concentrated to give the aldehyde, which was not further purified.
To a solution of diisopropylamine (896 mg, 8.85 mmol) in THF (5 ml) in a dry ice-acetone bath was added 1.6 M butyllithium in hexanes (5.5 ml, 8.8 mmol). After 5 min the mixture was put in an ice-water bath and stirred for 20 min. The solution was cooled in the dry ice-acetone bath again and a solution of the product of Step 5 (2.14 g, 7.37 mmol) in THF (8 ml) was added. The mixture was stirred for 1 h. A solution of the above aldehyde in THF (10 ml) was added and the mixture was stirred for 1.5 h. The reaction was quenched with water and partitioned between ether (4x50 ml) and water (50 ml). The combined organic layer was washed with brine (50 ml), dried (MgSO4), concentrated, and purified by column chromatography (gradient EtOAc/Hexanes 0-20%) to give the product (2.67 g, 52%). MS m/e 698 (M+H)+
Figure imgf000040_0001
A mixture of the product of Step 6 (194 mg, 0.277 mmol), 0.5 M propylzinc bromide in THF (2.2 ml), and Pd(dppf)CI2 (25 mg, 0.031 mmol) was degassed and heated to 450C in a sealed tube for 16 h. The mixture was diluted with CH2CI2 (50 ml) and washed with aqueous NH4OH (30 ml). The organic layer was dried (MgSO4), concentrated, and purified by PTLC (20% EtOAc/Hexanes) to give the product (124 mg, 68%). MS m/e 662 (M+H)+
Figure imgf000040_0002
A mixture of the product of Step 7 (124 mg, 0.188 mmol), 20% Pd(OH)2/C (169 mg), and catalytic amount of AcOH in EtOH (12 ml) was stirred under H2 (1 atm) for 4 h. The mixture was filtered and concentrated. The residue was partitioned between CH2CI2 (40 ml) and 1 N NaOH (20 ml). The organic layer was dried (MgSO4) and concentrated to give the product (81 mg, 89%). MS m/e 482 (M+H)+
Figure imgf000040_0003
A mixture of the product of Step 8 (81 mg, 0.17 mmol), triethylamine (24μl, 0.17 mmol), and acetic anhydride (17 mg, 0.17 mmol) in CH2CI2 (8 ml) was stirred in an ice-water bath for 2 h. The mixture was diluted with CH2CI2 (50 ml) and washed with 1 N NaOH (20 ml). The organic layer was dried (MgSO4), concentrated, and purified by PTLC (3% MeOH/CH2CI2) to give the product (81 mg, 91%). MS m/e 524 (M+H)+ Step iO
Figure imgf000041_0001
A solution of the product of Step 9 (81 mg, 0.15 mmol) and TFA (1 ml) in CH2CI2 (6 ml) was stirred in an ice-water bath for 1 h then at RT for 3 h. The mixture was diluted with CH2CI2 (40 ml) and washed with aqueous NH4OH (20 ml). The organic layer was dried (MgSO4), concentrated, and purified by PTLC (5% MeOH/CH2CI2) to give the product (42 mg, 67%). 1H-NMR (CDCI3): 5=7.1-7.4 (m, 8H), 7.01 (m, 1 H), 6.15 (m, 1 H), 4.72 (d, 1 H, J=14.8 Hz), 4.46 (m, 1 H), 4.35 (d, 1 H, J=14.8 Hz), 4.04 (m, 1 H), 3.40 (m, 1 H), 3.27 (m, 1 H), 3.06 (m, 2H), 2.95 (m, 1 H), 2.83 (m, 1 H), 2.65 (m, 1 H), 2.54 (t, 2H, J=7.6 Hz), 1.86 (s, 3H), 1.61 (m, 2H), 0.91 (t, 3H, J=7.4 Hz). LCMS tR=3.33 min m/e 424 (M+H)+
By essentially the same procedure set forth in Preparative Example 1 , the following examples were prepared.
Figure imgf000041_0002
Figure imgf000042_0001
Preparative Example 2
Figure imgf000042_0002
To a solution of 1 ,3-dibromo-5-fluorobenzene (5.105 g, 20.11 mmol) in ether (50 ml) in a dry ice-acetone bath was added 1.6M butyllithium in hexanes (12.5 ml, 20.0 mmol). After 2 h benzaldehyde (2.287 g, 21.55 mmol) was added and the mixture was allowed to warm to RT slowly and stirred for 16 h. The reaction was quenched with brine (70 ml) and the aqueous layer was extracted with ether (50 ml). The combined organic layer was dried (MgSO4), concentrated, and purified by column chromatography (gradient EtOAc/Hexanes 0-10%) to give the product (5.036 g, 90%). 1H-NMR (CDCI3): 6=7.30 (m, 6H), 7.09 (m, 1 H), 7.02 (m, 1 H), 5.73 (s, 1 H).
Figure imgf000043_0001
To a solution of the product of Step 1 (5.036 g, 17.92 mmol) in CH2CI2 (70 ml) was added triethylsilane (12.0 ml, 74.3 mmol). The solution was cooled in an ice- water bath and boron trifluoride diethyl etherate (3.35 ml, 26.7 mmol) was added. The mixture was slowly warmed to RT and stirred for 5 h. The reaction was cooled in an ice-water bath and quenched with saturated NaHCO3 (100 ml). The aqueous layer was extracted with CH2CI2 (50 ml) and the combined organic layer was dried (MgSO4) and concentrated to give the product (4.09 g, 86%). 1H-NMR (CDCI3): 6=7.28 (m, 2H), 7.20 (m, 1 H), 7.12 (m, 3H), 7.04 (m, 1 H)1 6.78 (m, 1 H), 3.90 (s, 2H).
Figure imgf000043_0002
To an ice-cold solution of N-Boc-D-serine methyl ester (10.0 g, 45.6 mmol) in DMF (150 ml) were added imidazole (9.26 g, 136 mmol) and TBSCI (7.56 g, 50.16 mmol). The mixture was stirred at RT for 20 h and concentrated. The residue was dissolved with EtOAc (300 ml) and extracted with saturated NH4CI and sodium bicarbonate. The organic layer was dried (MgSO4) and concentrated to give the product (16.5 g, 100%). MS m/e 356 (M+Na)+
TBSO^T^OMe -!^- TBSO^^OH NHBoc NHBoc
To a solution of the product of Step 3 (16.5 g, 45.6 mmol) in THF (150 ml) was added 2M lithium borohydride in THF (37.1 ml) slowly. The mixture was stirred at RT for 2.5 h. The reaction was quenched with saturated NH4CI and extracted with EtOAc (2x250 ml). The combined organic layer was washed with saturated NH4CI (100 ml), saturated sodium bicarbonate, and brine, dried, and concentrated to give the product (14.5 g, 100%). MS m/e 306 (M+H)+
Figure imgf000044_0001
To an ice-cold solution of triphenylphosphine (13.95 g, 53.19 mmol) in THF (400 ml) and CH3CN (50 ml) was added DIAD (10.76 g, 53.21 mmol). The mixture was stirred for 15 min and a solution of the product of Step 4 (8.20 g, 26.2 mmol) in THF (100 ml) was added over 15 min. After the addition was complete, the ice-water bath was removed and the mixture was stirred at RT for 2 d. The mixture was concentrated and purified by column chromatography (gradient EtOAc/Hexanes 0- 5%) to give the product (3.75 g, 50%). MS m/e 288 (M+H)+
OTBS
Figure imgf000044_0002
To a flame-dried flask were added magnesium turnings (499 mg, 20.5 mmol), the product of Step 2 (4.45 g, 16.8 mmol), drops of 1 ,2-dibromoethane, and anhydrous THF (20 ml). The mixture was stirred at RT for 1.5 h and added to a suspension of CuBr-Me2S (272 mg, 1.32 mmol) in THF (15 ml) in a dry ice-acetone bath. The mixture was stirred for 1.5 h and a solution of the product of Step 5 (2.52 g, 8.75 mmol) in anhydrous ether (20 ml) was added. The resulting mixture was warmed in an ice-water bath and allowed to slowly warm to RT and stirred for 3 d. The reaction was quenched with saturated NH4CI (100 ml) and extracted with EtOAc (2x150 ml). The combined organic layer was dried (MgSO4), concentrated, and purified by column chromatography (gradient EtOAc/Hexanes 0-8%) to give the product (1.51 g, 36%). MS m/e 474 (M+H)+
TBAF
Figure imgf000044_0003
Figure imgf000044_0004
A mixture of the product of Step 6 (710 mg, 1.50 mmol) and 1 M TBAF in THF (2.8 ml) in THF (10 ml) was stirred at RT for 5 h. The mixture was diluted with EtOAc (50 ml) and extracted with water (50 ml). The organic layer was dried (MgSO4), concentrated, and purified by column chromatography (gradient MeOH/CH2CI2 0- 2.5%) to give the product (508 mg, 94%). MS m/e 382 (M+Na)+
Figure imgf000045_0001
To a solution of oxalyl chloride (214 mg, 1.65 mmol) in CH2CI2 (2.5 ml) in a dry ice-acetone bath was added DMSO (356 mg, 4.56 mmol). After 5 min, a solution of the product of Step 7 (508 mg, 1.41 mmol) in CH2CI2 (3.5 ml) was added and the mixture was stirred for 1 h. Triethylamine (700 μl, 5.02 mmol) was added and the mixture was stirred for 15 min. The mixture was warmed to RT and stirred for 15 min. Water (30 ml) and CH2CI2 (40 ml) were added and the aqueous layer was extracted with CH2CI2 (30 ml). The combined organic layer was washed with brine (50 ml), dried (MgSO4), and concentrated to give the aldehyde, which was not further purified. To a solution of diisopropylamine (188 mg, 1.86 mmol) in THF (2.5 ml) in a dry ice-acetone bath was added 1.6 M butyllithium in hexanes (1.40 ml, 2.24 mmol). After 5 min the mixture was put in an ice-water bath and stirred for 20 min. The solution was cooled in the dry ice-acetone bath again and a solution of the product of Preparative Example 1 , Step 5 (460 mg, 1.59 mmol) in THF (4 ml) was added. The mixture was stirred for 1 h. A solution of the above aldehyde in THF (4 ml) was added and the mixture was stirred for 1.5 h. The reaction was quenched with water (40 ml) and extracted with ether (50 ml). The aqueous layer was extracted with ether (3x40 ml). The combined organic layer was washed with brine (50 ml), dried
(MgSO4), concentrated, and purified by PTLC (40% EtOAc/Hexanes) to give: fraction 1 (137 mg, 15%). MS m/e 648 (M+H)+; fraction 2 (148 mg, 16%). MS m/e 648 (M+H)+
Figure imgf000046_0001
A solution of the fraction 1 product of Step 8 (136 mg, 0.211 mmol) and TFA (1 ml) in CH2CI2 (5 ml) was stirred in an ice-water bath for 30 min then at RT for 2.5 h. The mixture was diluted with CH2CI2 (40 ml) and washed with aqueous NH4OH (10 ml). The organic layer was dried (Na2CO3), concentrated, and purified by PTLC (10% 2M NH3/MeOH-90% CH2CI2) to give the product (72 mg, 77%). MS m/e 448 (M+H)+
Step 10
Figure imgf000046_0002
To an ice-cold solution of the product of Step 9 (70 mg, 0.16 mmol) and triethylamine (16 mg, 0.16 mmol) in CH2CI2 (3 ml) was added acetic anhydride (14 mg, 0.14 mmol) in CH2CI2 (3 ml) over 1 h. The mixture was slowly warmed to RT and stirred for 2 h. The solution was diluted with CH2CI2 (40 ml) and washed with 0.5N NaOH (30 ml). The organic layer was dried (MgSO4), concentrated, and purified by PTLC (5% MeOH/CH2CI2) to give:
fraction A (24 mg, 36%). 1H-NMR (CDCI3): 5=7.15-7.35 (m, 9H), 6.86(s, 1 H), 6.79 (d, 1 H, J=9.6 Hz), 6.72 (d, 1 H, J=9.6 Hz), 6.17 (s, 1 H)1 5.92 (d, 1 H, J=10.4 Hz), 4.79 (d, 1 H1 J=15 Hz), 4.41 (m, 1 H), 4.35 (d, 1 H, J=15 Hz), 3.92 (s, 2H), 3.76 (d, 1 H, J=9 Hz), 3.47 (s, 2H), 3.36 (m, 1 H), 3.20 (d, 1 H, J=9 Hz), 3.05 (m, 2H), 2.90 (m, 3H), 1.89 (s, 3H). MS m/e 490 (M+H)+
fraction B (29 mg, 43%). 1H-NMR (CDCI3): 6=7.15-7.35 (m, 10H), 6.89 (s, 1 H), 6.84 (d, 1 H, J=9.6 Hz), 6.73 (d, 1 H, J=9.6 Hz), 6.08 (d, 1 H, J=9.2 Hz), 4.73 (d, 1 H, J=14.6 Hz), 4.42 (m, 1 H), 4.36 (d, 1 H, J=14.6 Hz), 4.03 (m, 1 H), 3.91 (s, 2H), 3.37 (d, 1 H, J=7.6 Hz), 3.25 (m, 1 H), 3.00 (m, 3H)1 2.79 (m, 1 H), 2.66 (m,1 H), 1.80 (s, 3H). MS m/e 490 (M+H)+
By essentially the same procedure set forth in Step 9 and Step 10, the following examples were prepared from fraction 2 product of Step 8:
fraction C (27 mg) MS m/e 490 (M+H)+
fraction D (28 mg) MS m/e 490 (M+H)+
Preparative Example 3
Figure imgf000047_0001
A solution of (S)-m-cyanophenylalanine (5.00 g, 26.3 mmol) and potassium carbonate (14.5 g, 105 mmol) in water (50 ml) was heated to reflux. Benzyl bromide (10.4 ml, 86.8 mmol) was added dropwise. After 1 h additional benzyl bromide (1.50 ml, 12.5 mmol) was added and the mixture was refluxed for 1 h. The mixture was cooled and extracted with ether (2x300 ml). The combined organic layer was washed with saturated NaHCU3 (100 ml) and brine, dried (MgSO-O, concentrated, and purified by column chromatography (gradient EtOAc/Hexanes 0-10%) to give the product (10.9 g, 90%). MS m/e 461 (M+H)+
OH
Figure imgf000047_0002
To a solution of the product of Step 1 (2.30 g, 4.99 mmol) in THF (25 ml) in a dry ice-acetone bath was added 1 M LiAIH4 in THF (10.0 ml) slowly and the mixture was stirred for 3.5 h. The reaction was quenched with saturated NH4CI (15 ml) and extracted with ether (2x100 ml). The combined organic layer was washed with brine, dried (MgSO4), and concentrated. The residue was dissolved in THF (300 ml) and 2M LiBH4 in THF (2 ml) was added. The mixture was stirred at RT for 18 h. The reaction was quenched with saturated NH4CI (10 ml) and extracted with ether (2x100 ml). The combined organic layer was washed with brine, dried (MgSO4), concentrated, and purified by column chromatography (gradient EtOAc/Hexanes 0- 40%) to give the product (1.26 g, 71%). MS m/e 357 (M+H)+
Figure imgf000048_0001
To a solution of oxalyl chloride (538 mg, 4.24 mmol) in CH2CI2 (6 ml) in a dry ice-acetone bath was added DMSO (662 mg, 8.48 mmol). After 5 min, a solution of the product of Step 2 (1.26 g, 3.53 mmol) in CH2CI2 (15 ml) was added and the mixture was stirred for 1 h. Triethylamine (1.71 g, 17.0 mmol) was added and the mixture was warmed to RT and stirred for 30 min. Water (30 ml) and CH2CI2 (50 ml) were added and the aqueous layer was extracted with CH2CI2 (2x100 ml). The combined organic layer was washed with water (50 ml) and brine, dried (MgSO4), and concentrated to give the aldehyde, which was not further purified. To a solution of diisopropylamine (472 mg, 4.67 mmol) in THF (3 ml) in a dry ice-acetone bath was added 1.6 M butyllithium in hexanes (2.92 ml, 4.67 mmol). After 5 min the mixture was put in an ice-water bath and stirred for 20 min. The solution was cooled in the dry ice-acetone bath again and a solution of the product of Preparative Example 1 , Step 5 (1.23 g, 4.24 mmol) in THF (10 ml) was added. The mixture was stirred for 1 h. A solution of the above aldehyde in THF (15 ml) was added and the mixture was stirred for 1 h. The reaction was quenched with saturated NH4CI (10 ml) and diluted with water (20 ml) and ether (100 ml). The aqueous layer was extracted with ether (2x50 ml). The combined organic layer was washed with 5% citric acid (50 ml), saturated NaHCO3 (50 ml), and brine (50 ml), dried (MgSO4), concentrated, and purified by column chromatography (gradient EtOAc/Hexanes 0- 40%) to give the product (820 mg, 36%). MS m/e 645 (M+H)+
Figure imgf000049_0001
A mixture of the product of Step 3 (64 mg, 0.10 mmol), 20% Pd(OH)2/C (40 mg), and formic acid (0.1 ml) in EtOH (3 ml) was stirred under H2 (1 atm) for 40 min. The mixture was filtered and concentrated. The residue and triethylamine (36 μl, 0.25 mmol) were dissolved in CH2CI2 (5 ml) and cooled in an ice-water bath. To the solution was added a solution of (BoC)2O (24 mg, 0.11 mmol) in CH2CI2 (1 ml) dropwise. The mixture was stirred in the ice-water bath for 1 h and concentrated. The residue was purified by PTLC (5% 2M NHs/MeOH -95% CH2CI2) to give the product (62 mg, 100%). MS m/e 569 (M+H)+
Figure imgf000049_0002
A solution of the product of Step 4 (62 mg, 0.11 mmol), acetic anhydride (12 mg, 0.12 mmol), and triethylamine (36 μl, 0.25 mmol) in CH2CI2 (4 ml) was stirred in an ice-water bath for 30 min. The mixture was concentrated and purified by PTLC (5% MeOH/CH2CI2) to give the product (51 mg, 76%). MS m/e 611 (M+H)+
Figure imgf000049_0003
A solution of the product of Step 5 (51 mg, 0.084 mmol) and TFA (1 ml) in CH2CI2 (4 ml) was stirred at RT for 30 min and concentrated. The residue was dissolved in CH2CI2 (50 ml) and washed with aqueous NH4OH (5 ml) and brine. The organic layer was dried (K2CO3) and concentrated to give the product (34 mg, 99%). MS m/e 411 (M+H)+
Figure imgf000050_0001
To an ice-cold solution of the product of Step 6 (32 mg, 0.078 mmol) and triethylamine (28 μl, 0.20 mmol) in CH2CI2 (2.5 ml) was added a solution of propylsulfonyl chloride (9.6 μl, 0.086 mmol) in CH2CI2 (0.5 ml). The mixture was stirred for 30 min and concentrated. The residue was purified by PTLC (5% 2M NH3/MeOH-95%CH2CI2) to give the product (27 mg, 66%). 1H-NMR (CDCI3): δ=7.05- 7.35 (m, 9H), 6.48 (d, 1 H, J=9.2 Hz), 5.52 (m, 1 H), 4.71 (d, 1 H, J=14.6 Hz), 4.47 (m, 1 H), 4.29 (d, 1 H, J=14.6 Hz), 4.17 (m, 2H), 4.02 (m, 1 H), 3.44 (m, 1 H), 3.25 (m, 1 H), 3.06 (m, 3H), 2.84 (m, 4H), 1.75 (m, 5H), 0.93 (t, 3H, J=7.4 Hz). LCMS tR=2.80 min m/e 517 (M+H)+
Preparative Example 4
Figure imgf000050_0002
Figure imgf000050_0003
A mixture of the product of Preparative Example 3, Step 3 (64 mg, 0.10 mmol), acetic anhydride (29 μl, 0.30 mmol), acetic acid (0.1 ml), and 20% Pd(OH)2/C (64 mg) in EtOH (3 ml) was stirred under H2 (1 atm) for 1.5 h. The mixture was concentrated and the residue was dissolved in CH2CI2 (30 ml). The solution was extracted with aqueous NH4OH and brine, dried (MgSO4), concentrated, and purified by PTLC (5% MeOH/CH2CI2) to give the product (14 mg, 25%). MS m/e 553 (M+H)+
Figure imgf000051_0001
A solution of the product of Step 1 (14 mg, 0.025 mmol) and TFA (1 ml) in
CH2CI2 (4 ml) was stirred at RT for 1.5 h. The mixture was concentrated and purified by PTLC (5% 2M NH3/MeOH-95%CH2CI2) to give the product (8 mg, 74%). 1H-NMR (CDCI3): 6=7.0-7.35 (m, 9H)1 6.11 (m, 1 H), 6.01 (b, 1 H), 5.15 (m, 1 H)1 4.67 (d, 1 H, J=14.8 Hz), 4.47 (m, 1 H), 4.33 (m, 3H), 3.99 (m, 1 H), 3.38 (m, 1 H), 3.26 (m, 1 H), 3.01 (m, 3H), 2.80 (m, 2H), 1.98 (s, 3H), 1.77 (s, 3H). LCMS tR=2.30 min m/e 453 (M+H)+
Preparative Example 5
Figure imgf000051_0002
Figure imgf000051_0003
To a suspension of 60% NaH (6.40 g, 0.160 mol) in anhydrous DMA (400 ml) was added allyl alcohol (8.90 g, 0.154 mol) slowly. The mixture was stirred at RT for 1 h. 3,5-Difluorobromobenzene (30.0 g, 0.155 mol) was added and the mixture was stirred at RT for 24 h. The reaction was quenched with water (1.5 I) and extracted with ether (4x300 ml). The combined organic layer was washed with brine (500 ml), dried (MgSO4), concentrated, and purified by column chromatography (Hexanes) to give the product (14.3 g, 40%). 1H-NMR (CDCI3): δ=6.81 (m, 2H), 6.53 (m, 1 H), 5.96 (m, 1 H), 5.34 (m, 2H), 4.46 (m, 2H).
Figure imgf000052_0001
To a flame-dried flask was added magnesium turnings (292 mg, 12.0 mmol) followed by one third of a solution of the product of Step 1 (2.31 g, 10.0 mmol) in THF (16 ml). The reaction was initiated with 1 ,2-dibromoethane (50 μl) then the remaining solution of the product of Step 1 was added slowly. The mixture was stirred at RT for 30 min and added to a suspension of CuBr-Me2S (310 mg, 1.51 mmol) in THF (30 ml) at -4O0C. The mixture was stirred at 40C for 30 min and a solution of the product of Preparative Example 2, Step 5 (1.20 g, 4.17 mmol) in anhydrous ether (15 ml) was added. The resulting mixture was stirred at 40C for 1 h then at RT for 3 d. The reaction was quenched with saturated NH4CI (100 ml) and extracted with EtOAc (2x150 ml). The combined organic layer was washed with saturated sodium bicarbonate and brine, dried (MgSO4), concentrated, and purified by column chromatography (gradient EtOAc/Hexanes 0-5%) to give the product (1.00 g, 55%). MS m/e 440 (M+H)+
H
Figure imgf000052_0002
A solution of the product of Step 2 (500 mg, 1.14 mmol) in CH2CI2 (12 ml) and 4N HCI/dioxane (6 ml) was stirred at RT for 20 h. The mixture was concentrated and the residue was partitioned between CH2CI2 (50 ml) and 5N NH4OH (20 ml). The organic layer was dried (K2CO3) and concentrated to give the product (345 mg, 100%). MS m/e 226 (M+H)+
Figure imgf000053_0001
A solution of the product of Step 3 (3.10 g, 13.0 mmol) and potassium carbonate (5.39 g, 39.0 mmol) in EtOH (30 ml) and water (90 ml) was heated to 7O0C. Benzyl bromide (3.42 ml, 28.6 mmol) was added and the mixture was stirred at 7O0C for 2.5 h. EtOH was removed and the residue was extracted with ether (2x200 ml). The organic layer was washed with brine, dried (K2CO3), concentrated, and purified by column chromatography (gradient 0-10% EtOAc/Hexanes) to give the product (4.40 g, 83%). MS m/e 406 (M+H)+
Figure imgf000053_0002
To a solution of oxalyl chloride (762 mg, 6.00 mmol) in CH2CI2 (10 ml) in a dry ice-acetone bath was added DMSO (938 mg, 12.0 mmol). After 5 min, a solution of the product of Step 4 (2.03 g, 5.01 mmol) in CH2CI2 (20 ml) was added and the mixture was stirred for 1 h. Triethylamine (2.42 g, 23.9 mmol) was added and after 2 min the cooling bath was removed. The mixture was stirred for 30 min and diluted with water (50 ml). CH2CI2 (100 ml) was added and the aqueous layer was extracted with CH2CI2 (2x100 ml). The combined organic layer was washed with brine, dried (MgSO4), and concentrated to give the aldehyde, which was not further purified.
To a solution of diisopropylamine (667 mg, 6.59 mmol) in THF (5 ml) in a dry ice-acetone bath was added 1.6 M butyllithium in hexanes (4.13 ml, 6.61 mmol). After 5 min the mixture was put in an ice-water bath and stirred for 20 min. The solution was cooled in the dry ice-acetone bath again and a solution of the product of Preparative Example 1 , Step 5 (1.74 g, 5.99 mmol) in THF (20 ml) was added. The mixture was stirred for 1 h. A solution of the above aldehyde in THF (30 ml) was added and the mixture was allowed to warm up to RT slowly and stirred for 16 h. The reaction was quenched with saturated NH4CI (20 ml) and extracted with ether (3x100 ml). The combined organic layer was washed with 5% citric acid, saturated NaHCO3, and brine, dried (Na2SO4), concentrated, and purified by column chromatography (gradient EtOAc/Hexanes 0-40%) to give the product (1.20 g, 35%). MS m/e 694 (M+H)+
Figure imgf000054_0001
A solution of the product of Step 5 (280 mg, 0.404 mmol) in MeOH (5 ml) was degassed with N2 for 5 min. Pd(PPh3)4 (70 mg, 0.061 mmol) was added and the mixture was degassed for another 5 min. Anhydrous potassium carbonate (166 mg, 1.20 mmol) was added and the mixture was stirred at RT for 18 h. The mixture was filtered and the filtrate was diluted with CH2CI2 (100 ml), washed with 5% citric acid, saturated NaHCO3 and brine. The organic layer was dried (MgSO4), concentrated, and purified by column chromatography (gradient EtOAc/Hexanes 0-20%) to give the product (230 mg, 87%). MS m/e 654 (M+H)+
Figure imgf000054_0002
A mixture of the product of Step 6 (230 mg, 0.352 mmol), 20% Pd(OH)2/C (230 mg), and acetic acid (0.5 ml) in EtOH (12 ml) was stirred under H2 (1 atm) for 16 h. The mixture was filtered, concentrated, and taken up in CH2CI2 (20 ml). Acetic anhydride (36 mg, 0.35 mmol) and triethylamine (0.40 ml, 2.9 mmol) were added and the mixture was stirred in an ice-water bath for 1.5 h. The mixture was concentrated and purified by column chromatography (gradient MeOH/CH2CI2 0-5%) to give the product (148 mg, 82%). MS m/e 516 (M+H)+
Figure imgf000055_0001
A mixture of the product of Step 7 (15 mg, 0.029 mmol), 4-bromomethyl pyridine (15 mg, 0.058 mmol), and potassium carbonate (40 mg, 0.29 mmol) in DMF (2.5 ml) was stirred at RT for 3 d. The mixture was diluted with CH2CI2 (50 ml), extracted with water (3x50 ml) and saturated NaHCO3, dried (MgSO4), and concentrated. The residue was dissolved in CH2CI2 (5 ml) and TFA (1 ml). The mixture was stirred at RT for 2.5 h, concentrated, and purified by PTLC (10% 2M NH3/MeOH-90% CH2CI2) to give the product (9 mg, 63%). 1H-NMR (CDCI3): δ=8.57 (m, 2H), 7.15-7.35 (m, 7H), 6.67 (s, 1 H)1 6.58 (m, 1 H), 6.48 (m, 1 H), 6.02 (d, 1 H, J=8.8 Hz), 5.07 (b, 1 H), 5.01 (s, 2H), 4.68 (d, 1 H, J=14.6 Hz), 4.42 (m, 1 H), 4.36 (d, 1 H, J=14.6 Hz), 3.99 (m, 1 H), 3.37 (m, 1 H), 3.27 (m, 1 H), 3.03 (m, 3H), 2.76 (m, 2H), 1.82 (s, 3H), 1.69 (m, 2H). LCMS tR=2.17 min m/e 507 (M+H)+
By essentially the same procedure set forth in Preparative Example 5, the following examples were prepared.
Figure imgf000055_0002
Figure imgf000056_0001
Preparative Example 6
Figure imgf000056_0002
Stepj
Figure imgf000056_0003
A mixture of the product of Preparative Example 5, Step 7 (15 mg, 0.029 mmol), 2-pyridylcarbinol (9.5 mg, 0.087 mmol), DIAD (18 mg, 0.087 mmol), and triphenylphosphine (23 mg, 0.087 mmol) in CH2CI2 (1 ml) was stirred at RT for 24 h. The mixture was concentrated and purified by PTLC (5% MeOH/CH2CI2) to give the product (20 mg, 100%). MS m/e 607 (M+H)+
Figure imgf000057_0001
A solution of the product of Step 1 (20 mg, 0.029 mmol) and TFA (0.5 ml) in CH2CI2 (3 ml) was stirred at RT for 2 h. The mixture was concentrated and purified by PTLC (5% 2M NH3/MeOH-95% CH2CI2) to give the product (8 mg, 57%). 1H-NMR (CDCI3): 6=8.54 (m, 1 H), 7.68 (m, 1 H), 7.45 (m, 1 H), 7.15-7.35 (m, 6H), 6.69 (s, 1 H), 6.54 (m, 2H), 6.08 (d, 1 H, J=8.8 Hz), 5.11 (s, 2H), 4.70 (d, 1 H, J=14.6 Hz), 4.40 (m, 1 H), 4.33 (d, 1 H, J=14.6 Hz), 4.04 (m, 1 H), 3.42 (d, 1 H, J=7.6 Hz), 3.27 (m, 1 H), 3.04 (m, 3H), 2.76 (m, 2H), 1.85 (m, 2H), 1.81 (s, 3H). LCMS tR=2.25 min m/e 507 (M+H)+
By essentially the same procedure set forth in Preparative Example 6, the following examples were prepared.
Figure imgf000057_0002
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0002
Preparative Example 7
Figure imgf000060_0001
A mixture of the product of Preparative Example 5, Step 5 (140 mg, 0.202 mmol), acetic acid (0.2 ml), and 20% Pd(OH)2/C (90 mg) in EtOH (5 ml) was stirred under H2 for 1.5 h. The mixture was filtered, concentrated, and dissolved in CH2CI2 (5 ml). To this solution were added acetic anhydride (21 μl, 0.22 mmol) and triethylamine (100 μl, 0.717 mmol). The mixture was stirred at RT for 25 min. MeOH (1 ml) was added and the mixture was concentrated. The residue was purified by PTLC (5% MeOH/CH2CI2) to give the product (75 mg, 67%). MS m/e 558 (M+H)+
Figure imgf000061_0001
A solution of the product of Step 1 (75 mg, 0.13 mmol) and TFA (1 ml) in CH2CI2 (5 ml) was stirred at RT for 30 min. The mixture was concentrated and purified by PTLC (5% 2M NH3/MeOH-95% CH2CI2) to give the product (67 mg, 100%). 1H-NMR (CDCI3): 5=7.1-7.35 (m, 5H), 6.25-6.6 (m, 4H), 4.75 (m, 1 H), 4.44 (m, 1 H), 4.32 (m, 1 H), 4.11 (m, 1 H), 3.84 (m, 2H), 3.49 (m, 1 H), 3.29 (m, 1 H), 3.06 (m, 3H), 2.78 (m, 2H), 1.83 (s, 3H), 1.73 (m, 2H), 1.00 (t, 3H, J=7.4 Hz). LCMS tR=3.14 min m/e 458 (M+H)+
Preparative Example 8
Figure imgf000061_0002
A mixture of the product of Preparative Example 5, Step 5 (69 mg, 0.099 mmol), 5-bromopentene (90 mg, 0.60 mmol), and 2nd generation Grubbs catalyst (19 mg, 0.022 mmol) in CH2CI2 (5 ml) was degassed and heated to 5O0C for 6.5 h. The mixture was concentrated and purified by PTLC (5% MeOH/CH2CI2) to give the product (60 mg, 74%). MS m/e 814 (M+H)+
Figure imgf000062_0001
A mixture of the product of Step 1 (60 mg, 0.074 mmol), acetic acid (0.2 ml), and 20% Pd(OH)2/C (50 mg) in EtOH (3 ml) was stirred under H2 for 2 h. The mixture was filtered and concentrated to give the product (39 mg, 95%). MS m/e 558 (M+H)+
Figure imgf000062_0002
A solution of the product of Step 2 (39 mg, 0.070 mmol) and acetic anhydride (9 mg, 0.08 mmol) in CH2CI2 (2.5 ml) was stirred at RT for 2.5 h. The mixture was concentrated and purified by PTLC (5% MeOH/CH2CI2) to give the product (36 mg, 86%). MS m/e 600 (M+H)+
Figure imgf000062_0003
A solution of the product of Step 3 (36 mg, 0.060 mmol) and TFA (0.3 ml) in
CH2CI2 (2 ml) was stirred at RT for 1.5 h. The mixture was concentrated and purified by PTLC (5% 2M NH3/MeOH-95% CH2CI2) to give the product (19 mg, 62%). 1H- NMR (CDCI3): 6=7.15-7.35 (m, 5H), 6.59 (s, 1 H), 6.52 (m, 1 H), 6.40 (m, 1 H), 6.09 (d, 1 H, J=9.2 Hz), 4.70 (d, 1 H, J=14.8 Hz), 4.43 (m, 1 H), 4.32 (d, 1 H, J=14.8 Hz), 4.04 (m, 1 H), 3.85 (m, 2H), 3.40 (m, 1 H), 3.26 (m, 1 H), 3.01 (m, 3H), 2.75 (m, 2H), 1.96 (b, 2H), 1.82 (s, 3H), 1.68 (m, 2H), 1.2-1.5 (m, 6H), 0.85 (m, 3H). LCMS tR=3.69 min m/e 500 (M+H)+ By essentially the same procedure set forth in Preparative Example 8, the following example was prepared.
Figure imgf000063_0001
Preparative Example 9
Figure imgf000063_0002
A mixture of the product of Preparative Example 5, Step 6 (1.50 g, 2.29 mmol), 20% Pd(OH)2/C (0.70 g), and acetic acid (1 ml) in EtOH (50 ml) was stirrded under H2 (1 atm) for 4 h. The mixture was filtered and concentrated to give the product (1.04 g, 96%). MS m/e 474 (M+H)+
Step 2
Figure imgf000063_0003
A mixture of the product of Step 1 (1.04 g, 2.20 mmol) and 2M BH3-SMe2 (8.0 ml) in THF (100 ml) was heated at 650C for 18 h. MeOH (10 ml) was added slowly and the heating continued for 1 h. The mixture was evaporated to dryness and the residue was dissolved in MeOH (50 ml). The resulting solution was concentrated and to the residue in CH2CI2 (60 ml) were added NEt3 (833 mg, 8.25 mmol) and acetic anhydride (281 mg, 2.75 mmol). The mixture was stirred at RT for 30 min and concentrated. 7N NH3 in MeOH (50 ml) was added and the resulting solution was stirred for 1 h. The mixture was concentrated and purified by column chromatography (gradient MeOH/CH2CI2 0-3%) to give the product (680 mg, 62%). MS m/e 502 (M+H)+
Figure imgf000064_0001
A mixture of the product of Step 2 (300 mg, 0.600 mmol), 20% Pd(OH)2/C (200 mg), and acetic acid (0.2 ml) in EtOH (15 ml) was stirrded under H2 (1 atm) for 1.25 h. The mixture was filtered and concentrated. The residue was dissolved in CH2CI2 (20 ml) and cooled in an ice-water bath. Triethylamine (182 mg, 1.80 mmol) and m- toluenesulfonyl chloride (115 mg, 0603 mmol) were added. The mixture was stirred for 30 min, diluted with CH2CI2 (150 ml), washed with 5% citric acid and saturated sodium bicarbonate, dried, and purified by column chromatography (gradient MeOH/CH2CI2 0-4%) to give the product (170 mg, 50%). MS m/e 566 (M+H)+
Step 4
Figure imgf000064_0002
A solution of the product of Step 3 (28 mg, 0.050 mmol), pyridazinemethanol
(17 mg, 0.15 mmol), triphenylphosphine (39 mg, 0.15 mmol), and DIAD (31 mg, 0.15 mmol) was stirred at RT for 1 h. The mixture was concentrated and pirified by PTLC (5% MeOH/CH2CI2) to give the product (32 mg, 97%). MS m/e 658 (M+H)+
Figure imgf000065_0001
A solution of the product of Step 4 (32 mg, 0.048 mmol) and TFA (1 ml) in CH2CI2 (5 ml) was stirred at RT for 1 h. The mixture was concentrated and pirified by PTLC (5% 2M NHa/MeOH in CH2CI2) to give the product (21 mg, 77%). %). 1H-NMR (CDCI3): δ=9.21 (s, 1 H), 9.14 (m, 1 H), 7.49 (m, 3H), 7.38 (m, 2H), 6.63 (s, 1 H), 6.56 (m, 1 H), 6.48 (m, 1 H), 6.39 (m, 1 H), 4.24 (m, 1 H), 3.65 (m, 2H), 3.32 (m, 1 H), 2.7-3.1 (m, 5H), 2.44 (m, 2H), 2.37 (s, 3H), 1.80 (s, 3H). LCMS tR=2.62 min m/e 558 (M+H)+
By essentially the same procedure set forth in Preparative Example 9, the following examples were prepared.
Figure imgf000065_0002
Figure imgf000066_0001
Preparative Example 10
Figure imgf000066_0002
A mixture of the product of Preparative Example 9, Step 2 (50 mg, 0.10 mmol), 1-bromo-2-pentene (33 mg, 0.22 mmol), and potassium carbonate (138 mg, 0.100 mmol) in acetone (5 ml) was heated at 6O0C for 18 h. The mixture was filtered and concentrated to give the product (50 mg, 88%). MS m/e 570 (M+H)+
Figure imgf000066_0003
A mixture of the product of Step 1 (50 mg, 0.088 mmol), 20% Pd(OH)2/C (50 mg), and acetic acid (0.1 ml) in EtOH (5 ml) was stirrded under H2 (1 atm) for 16 h. The mixture was filtered and concentrated to give the product (35 mg, 83%). MS m/e 482 (M+H)+
Figure imgf000067_0001
A mixture of the product of Step 2 (35 mg, 0.072 mmol), m-toluenesulfonyl chloride (14 mg, 0.072 mmol), and triethylamine (35 mg, 0.35 mmol) in CH2CI2 (5 ml) was stirred in an ice-water bath for 30 min. The mixture was concentrated and purified by PTLC (5% MeOH/CH2CI2) to give the product (30 mg, 66%). MS m/e 636 (M+H)+
Figure imgf000067_0002
A solution of the product of Step 3 (30 mg, 0.047 mmol) and TFA (1 ml) in CH2CI2 (5 ml) was stirred at RT for 1 h. The mixture was concentrated and purified by PTLC (5% 2M NH3 in MeOH/95% CH2CI2) to give the product (22 mg, 89%). 1H-NMR (CDCI3): 6=7.50 (m, 2H), 7.36 (m, 2H), 6.43 (m, 3H), 5.93 (m, 1 H), 4.15 (m, 1 H), 3.84 (m, 2H), 3.65 (m, 2H), 3.39 (m, 1 H), 3.02 (m, 1 H), 2.83 (m, 4H), 2.39 (m, 5H), 1.85 (s, 3H), 1.70 (m, 2H), 1.33 (m, 4H), 0.88 (m, 3H). LCMS tR=3.52 min m/e 536 (M+H)+
Preparative Example 11
Figure imgf000067_0003
Figure imgf000068_0001
A mixture of the product of Preparative Example 1 , Step 6 (142 mg, 0.203 mmol), phenylboronic acid (32 mg, 0.25 mmol), PS-PPh3-Pd (160 mg, 0.016 mmol), and 1 M aqueous potassium carbonate (0.25 ml) in EtOH (3 ml) was degassed, sealed, and heated at 1000C in a microwave reactor for 15 min. The mixture was diluted with MeOH (40 ml), filtered, concentrated, and purified by PTLC (20% EtOAc/Hexanes) to give the product (96 mg, 68%). MS m/e 696 (M+H)+
Figure imgf000068_0002
A mixture of the product of Step 1 (96 mg, 0.14 mmol), catalytic amount of acetic acid, and 20% Pd(OH)2/C (150 mg) in MeOH (12 ml) was stirred under H2 (1 atm) for 6 h. The mixture was filtered through a Celite pad and concentrated. The residue was partitioned between CH2CI2 (40 ml) and NH4OH (15 ml). The organic layer was dried over MgSO4 and concentrated to give the product (57 mg, 80%). MS m/e 516 (M+H)+
Figure imgf000068_0003
A mixture of the product of Step 2 (57 mg, 0.11 mmol), acetic anhydride (13 mg, 0.12 mmol), and triethylamine (20 μl, 0.14 mmol) in CH2CI2 (10 ml) was stirred in an ice-water bath for 1 h then at RT for 3 h. The mixture was diluted with CH2CI2 (40 ml) and extracted with 1 N NaOH (15 ml). The organic layer was dried (MgSO4), concentrated, and purified by PTLC (4% MeOH/CH2CI2) to give the product (63 mg, 100%). MS m/e 558 (M+H)+
Figure imgf000069_0001
A solution of the product of Step 3 (63 mg, 0.11 mmol) and TFA (0.9 ml) in CH2CI2 (4 ml) was stirred at RT for 3 h. The mixture was diluted with CH2CI2 (40 ml) and extracted with NH4OH (15 ml). The organic layer was dried (MgSO4), concentrated, and purified by PTLC (5% MeOH/CH2CI2) to give the product (39 mg, 77%). 1H-NMR (CDCI3): 5=7.1-7.6 (m, 14H), 6.28 (m, 1 H), 4.69 (m, 1 H), 4.48 (m,
1 H), 4.30 (m, 1 H), 4.05 (m, 1 H), 3.39 (m, 1 H), 3.24 (m, 1 H), 2.8-3.2 (m, 4H), 2.67 (m, 1 H), 1.80 (s, 3H). LCMS tR=3.16 min m/e 458 (M+H)+
By essentially the same procedure set forth in Preparative Example 11 , the following examples were prepared.
Figure imgf000069_0002
Figure imgf000070_0001
Preparative Example 12
Figure imgf000070_0002
Step i
Figure imgf000070_0003
A mixture of the product of Preparative Example 1 , Step 6 (191 mg, 0.273 mmol), N-t-butoxycarbonylpiperazine (78 mg, 0.42 mmol), cesium carbonate (345 mg, 1.06 mmol), BINAP (70 mg, 0.11 mmol), and palladium acetate (32 mg, 0.14 mmol) in dry toluene (8 ml) was heated at 950C for 16 h. The mixture was filtered, concentrated, and purified by PTLC (2% MeOH/CH2CI2) to give the product (96 mg, 44%). MS m/e 804 (M+H)+
Figure imgf000071_0001
A mixture of the product of Step 1 (96 mg, 0.12 mmol), catalytic amount of acetic acid, and 20%Pd(OH)2/C (140 mg) in MeOH (10 ml) was stirred under H2 (1 atm) for 4 h. The mixture was filtered and evaporated to dryness. The residue was dissolved in CH2CI2 (40 ml) and extracted with NH4OH (10 ml). The organic layer was dried (MgSO4) and concentrated to give the product (56 mg, 74%). MS m/e 624 (M+H)+
Figure imgf000071_0002
A mixture of the product of Step 2 (56 mg, 0.089 mmol), acetic anhydride (9.5 mg, 0.093 mmol), and triethylamine (25 μl, 0.18 mmol) in CH2CI2 (10 ml) was stirred in an ice-water bath for 1 h then at RT for 16 h. The mixture was concentrated and purified by PTLC (3% MeOH/CH2CI2) to give the product (51 mg, 86%). MS m/e 666 (M+H)+
Figure imgf000071_0003
A solution of the product of Step 3 (51 mg, 0.077 mmol) and TFA (1 ml) in CH2CI2 (5 ml) was stirred at RT for 4 h. The mixture was diluted with CH2CI2 (40 ml) and extracted with NH4OH (15 ml). The organic layer was dried (MgSO4), concentrated, and purified by PTLC (15% MeOH/CH2CI2) to give the product (24 mg, 68%). 1H-NMR (CDCI3): δ=7.1-7.3 (m, 6H), 6.85 (s, 1 H), 6.72 (m, 2H), 6.18 (m, 1 H), 4.67 (m, 1 H), 4.42 (m, 1 H), 4.31 (m, 1 H), 4.00 (m, 1 H), 3.36 (m, 1 H), 3.23 (m, 1 H), 2.6-3.1 (m, 14H), 1.82 (s, 3H). LCMS tR=2.16 min m/e 466 (M+H)+
BACE-I Cloning, Protein Expression and Purification. A predicted soluble form of human BACE1 (sBACEI , corresponding to amino acids 1-454) was generated from the full length BACE1 cDNA (full length human BACE 1 cDNA in pCDNA4/mycHisA construct; University of Toronto) by PCR using the advantage-GC cDNA PCR kit (Clontech, Palo Alto, CA). A Hindlll/Pmel fragment from pCDNA4-sBACE1 myc/His was blunt ended using Klenow and subcloned into the Stu I site of pFASTBACI(A) (Invitrogen). A sBACEI mycHis recombinant bacmid was generated by transposition in DHIOBac cells(GIBCO/BRL). Subsequently, the sBACEI mycHis bacmid construct was transfected into sf9 cells using CellFectin (Invitrogen, San Diego, CA) in order to generate recombinant baculovirus. Sf9 cells were grown in SF 900-11 medium (Invitrogen) supplemented with 3% heat inactivated FBS and 0.5X penicillin/streptomycin solution (Invitrogen). Five milliliters of high titer plaque purified sBACEmyc/His virus was used to infect 1 L of logarithmically growing sf9 cells for 72 hours. Intact cells were pelleted by centrifugation at 3000xg for 15 minutes. The supernatant, containing secreted sBACEI , was collected and diluted 50% v/v with 100 mM HEPES, pH 8.0. The diluted medium was loaded onto a Q- sepharose column. The Q-sepharose column was washed with Buffer A (20 mM HEPES, pH 8.0, 50 mM NaCI).
Proteins, were eluted from the Q-sepharose column with Buffer B (20 mM HEPES, pH 8.0, 500 mM NaCI). The protein peaks from the Q-sepharose column were pooled and loaded onto a Ni-NTA agarose column. The Ni-NTA column was then washed with Buffer C (20 mM HEPES, pH 8.0, 500 mM NaCI). Bound proteins were then eluted with Buffer D (Buffer C+250 mM imidazole). Peak protein fractions as determined by the Bradford Assay (Biorad, CA) were concentrated using a Centricon 30 concentrator (Millipore). sBACEI purity was estimated to be -90% as assessed by SDS-PAGE and Commassie Blue staining. N-terminal sequencing indicated that greater than 90% of the purified sBACEI contained the prodomain; hence this protein is referred to as sproBACEL
Peptide Hydrolysis Assay.
The inhibitor, 25 nM EuK-biotin labeled APPsw substrate (EuK- KTEEISEVNLDAEFRHDKC-biotin; CIS-Bio International, France), 5 μM unlabeled APPsw peptide (KTEEISEVNLDAEFRHDK; American Peptide Company, Sunnyvale, CA), 7 nM sproBACEI , 20 mM PIPES pH 5.0, 0.1%Brij-35 (protein grade, Calbiochem, San Diego, CA), and 10% glycerol were preincubated for 30 min at 3O0C. Reactions were initiated by addition of substrate in a 5 μl aliquot resulting in a total volume of 25 μl. After 3 hr at 30° C reactions were terminated by addition of an equal volume of 2x stop buffer containing 50 mM Tris-HCI pH 8.0, 0.5 M KF, 0.001% Brij-35, 20 μg/ml SA-XL665 (cross-linked allophycocyanin protein coupled to streptavidin; CIS-Bio International, France) (0.5 μg/well). Plates were shaken briefly and spun at 1200xg for 10 seconds to pellet all liquid to the bottom of the plate before the incubation. HTRF measurements were made on a Packard Discovery® HTRF plate reader using 337 nm laser light to excite the sample followed by a 50 μs delay and simultaneous measurements of both 620 nm and 665 nm emissions for 400 μs.
IC50 determinations for inhibitors, (/), were determined by measuring the percent change of the relative fluorescence at 665 nm divided by the relative fluorescence at 620 nm, (665/620 ratio), in the presence of varying concentrations of / and a fixed concentration of enzyme and substrate. Nonlinear regression analysis of this data was performed using GraphPad Prism 3.0 software selecting four parameter logistic equation, that allows for a variable slope. Y=Bottom + (Top-Bottom)/ (1
Figure imgf000073_0001
Slope)); X is the logarithm of concentration of I, Y is the percent change in ratio and Y starts at bottom and goes to top with a sigmoid shape.
Compounds of the present invention have an IC5O range from about 100 to about 10,000 nM, preferably about 100 to about 1000 nM, more preferably about 100 to about 500 nM. Compounds of the preferred stereochemistry have IC5O values in a range of about 2 to about 500 nM, preferably about 2 to about 100 nM.
The compound of the following formula
Figure imgf000074_0001
has a IC50 Of 186 nM.
While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

Claims

We claim:
1. A compound having the structural formula
Figure imgf000075_0001
or a pharmaceutically acceptable salt thereof, wherein R1 is
Figure imgf000075_0002
R2 is hydrogen, alkyl or cycloalkyl;
R3 is arylene, heteroarylene, heterocyclylene or cycloalkylene; R4 is hydrogen, -C(O)-alkyl, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, alkoxyalkyl, heterocyclyl, heterocyclylalkyl, heteroaralkyl or heteroaryl;
R5 and R7 are 1 to 4 moieties, each moiety being independently selected from hydrogen, -OH, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, aralkoxy, heteroaralkoxy and alkoxy, with the proviso that when R5 and R7 are -OH, aralkoxy, heteroaralkoxy and alkoxy, R5 and R7 are not attached to a ring carbon adjacent to a ring nitrogen;
R6 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, -C(O)R8, -C(O)OR11, -S(O)R8, -S(O2)R8 or -CN; with the proviso that when Y is =0, R6 cannot be -C(O)R8, -C(O)OR11, -S(O)R8, -S(O2)R8 or -CN;
R8 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl or -N(R9)(R10);
R9 and R10 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl, heterocyclylalkyl, alkenyl and alkynyl; or R9 and R10 together with the nitrogen to which they are attached, form a 3-7 membered heterocyclyl ring;
R11 is alkyl, cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, alkenyl or alkynyl; X is a bond connecting R3 and R4, -O-, -S-, alkylene, -alkyleneNH-,
-alkyleneNHC(O)-, -alkyleneNHSO2-, -NH-, -NHC(O)-, or -NHSO2-; Y is =O or (H, H); m is O, 1 , 2, or 3; and n is 1 , 2, or 3; wherein each alkyl is optionally substituted with 1 to 3 moieties selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl)2, carboxy and -C(O)O-alkyl; and wherein each arylene, heteroarylene, heterocyclylalkyl, heterocyclylene, cycloalkylene, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl, aralkoxy or heteroaralkoxy is optionally substituted with 1 to 4 moieties selected from the group consisting of -CF3, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, arylalkenyl, heteroarylalkenyl, arylalkynyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, -C(=N-CN)-NH2, -C(=NH)-NH2, -C(=NH)-NH(alkyl), YiY2N-, YiY2N-alkyl-, YiY2NC(O)-, YiY2NSO2- and -SO2NY1Y2, wherein Yi and Y2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, -C(O)alkyl and aralkyl, with the proviso that cycloalkyl, cycloalkylene, heterocyclyl and heterocyclylene can be substituted with =0.
2. The compound of claim 1 wherein
Figure imgf000077_0001
and n is 2.
3. The compound of claim 1 wherein R 2 : is, alkyl.
4. The compound of claim 3 wherein R2 methyl.
5. The compound of claim 1 wherein R3 is arylene or halo-substituted arylene.
6. The compound of claim 5 wherein R3 is phenylene or fluoro substituted phenylene.
7. The compound of claim 1 wherein R4 is hydrogen, -C(O)-alkyl, alkyl, aryl, aralkyl, substituted aryl, substituted aralkyl, alkoxyalkyl, heteroaralkyl, substituted heteroaryl, substituted heteroaralkyl, alkoxyalkyl, heterocyclyl, heterocyclylalkyl, substituted heterocyclyl, substituted heterocyclylalkyl or heteroaryl.
8. The compound of claim 7 wherein R4 is hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, -C(O)Oethyl,
Figure imgf000077_0002
Figure imgf000078_0001
Figure imgf000079_0001
9. The compound of claim 1 wherein R5 and R7 are hydrogen, alkyl substituted by a cycloalkyl group, alkyl substituted by an aryl or heteroaryl group.
10. The compound of claim 1 wherein R6 is aralkyl or -S(O)2-R8.
11. The compound of claim 1 wherein R6 is
Figure imgf000079_0002
12. The compound of claim 1 wherein X is a bond connecting R3 and R4, O, alkylene, -alkyl-NHSO2- or -alkyl-NHC(O)-; Y is O and n is 2.
13. The compound of claim 1 wherein
Figure imgf000079_0003
R2 is alkyl;
R3 is phenylene or halo-substituted phenylene;
R4 is hydrogen, -C(O)-alkyl, alkyl, aryl, aralkyl, substituted aryl, substituted aralkyl, alkoxyalkyl, heteroaralkyl, substituted heteroaryl, substituted heteroaralkyl, alkoxyalkyl, heterocyclyl, heterocyclylalkyl, substituted heterocyclyl, substituted heterocyclylalkyl or heteroaryl; R5 and R7 are hydrogen, alkyl substituted by a cycloalkyl group, alkyl substituted by an aryl or heteroaryl group;
R° is aralkyl or -S(O)2R 8.
Figure imgf000080_0001
X is a bond connecting R3 and R4, O, alkylene, -alkyl-NHSO2- or
-alkyl-NHC(O)-; and
Y is O.
14. The compound of claim 13 wherein R is methyl.
15. The compound of claim 13 wherein R3 is
Figure imgf000080_0002
16. The compound of claim 13 wherein R4 is hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, -C(O)Oethyl,
Figure imgf000080_0003
-80-
Figure imgf000081_0001
Figure imgf000082_0001
17. The compound of claim 13 wherein R is
Figure imgf000082_0002
18. The compound of claim 13 wherein R7 is hydrogen.
19. The compound of claim 13 wherein X is a bond connecting R3 and R4, O, alkylene, -alkyl-NHSO2- or -alkyl-NHC(O)-; Y is O and n is 2.
20. A compound of claim 1 having the stereochemical structure
Figure imgf000082_0003
21. A compound of claim 1 selected from the group consisting of
Figure imgf000082_0004
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000084_0002
Figure imgf000085_0001
Figure imgf000085_0002
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000087_0002
Figure imgf000088_0001
Figure imgf000088_0002
Figure imgf000088_0003
Figure imgf000088_0004
Figure imgf000089_0001
Figure imgf000089_0002
Figure imgf000089_0003
Figure imgf000089_0004
Figure imgf000090_0001
and
Figure imgf000090_0002
22. A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceutically effective carrier.
23. A compound of claim 1 in purified form.
24. A compound of claim 1 in isolated form.
25. A method of inhibiting the formation, or the formation and deposition of β- amyloid plaques in, on or around neurological tissue comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1.
26. A method of treating a cognitive or neurodegenerative disease comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1.
27. The method of claim 26 wherein Alzheimer's disease is treated.
28. A pharmaceutical composition comprising an effective amount of a compound of claim 1 , and an effective amount of a cholinesterase inhibitor in a pharmaceutically effective carrier.
29. A method of treating a cognitive or neurodegenerative disease comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1 in combination with an effective amount of a cholinesterase inhibitor.
30. The method of claim 29 where said cholinesterase inhibitor is acetyl¬ cholinesterase or butyrylchlolinesterase.
31. The method of claim 29 wherein said cholinesterase inhibitor is selected from the group consisting of tacrine, donepezil, rivastigmine, galantamine, pyridostigmine and neostigmine.
32. A method of treating a cognitive or neurodegenerative disease comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1 in combination with an effective amount of an anti-inflammatory compound.
33. The method of claim 32 wherein said anti-inflammatory compound is a non¬ steroidal anti-inflammatory drug.
34. The method of claim 33 wherein said non-steroid anti-inflammatory drug is diclofenac, diflunisal, etodolac, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, celecoxib or rofecoxib.
35. A method of treating a cognitive or neurodegenerative disease comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1 in combination with an effective amount of a gamma secreatse inhibitor.
36. A method of treating a cognitive or neurodegenerative disease comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1 in combination with an effective amount of an HMG-CoA reductase inhibitor compound.
37. The method of claim 36 wherein said HMG-CoA reductase inhibitor compound is atorvastatin, lovastatin, simvistatin, pravastatin, fluvastatin or rosuvastatin.
38. A method of treating a cognitive or neurodegenerative disease comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1 in combination with an effective amount of a N-methyl-D- aspartate receptor antagonist.
39. The method of claim 38 wherein said N-methyl-D-aspartate receptor antagonist is memantine.
40. A method of treating a cognitive or neurodegenerative disease comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1 in combination with an effective amount of an anti-amyloid antibody.
PCT/US2005/025780 2004-07-22 2005-07-20 Substituted amide beta secretase inhibitors WO2006014762A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT05773473T ATE491693T1 (en) 2004-07-22 2005-07-20 SUBSTITUTED AMIDES AS INHIBITORS OF BETA SECRETASE
JP2007522711A JP2008507538A (en) 2004-07-22 2005-07-20 Substituted amide β-secretase inhibitor
CA002574218A CA2574218A1 (en) 2004-07-22 2005-07-20 Substituted amide beta secretase inhibitors
EP05773473A EP1781625B1 (en) 2004-07-22 2005-07-20 Substituted amide beta secretase inhibitors
MX2007000760A MX2007000760A (en) 2004-07-22 2005-07-20 Substituted amide beta secretase inhibitors.
DE602005025363T DE602005025363D1 (en) 2004-07-22 2005-07-20 SUBSTITUTED AMIDS AS INHIBITORS OF BETA-SEKRETASE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59010204P 2004-07-22 2004-07-22
US60/590,102 2004-07-22

Publications (1)

Publication Number Publication Date
WO2006014762A1 true WO2006014762A1 (en) 2006-02-09

Family

ID=35431616

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025780 WO2006014762A1 (en) 2004-07-22 2005-07-20 Substituted amide beta secretase inhibitors

Country Status (12)

Country Link
US (2) US7803802B2 (en)
EP (1) EP1781625B1 (en)
JP (1) JP2008507538A (en)
CN (1) CN101014577A (en)
AR (1) AR049726A1 (en)
AT (1) ATE491693T1 (en)
CA (1) CA2574218A1 (en)
DE (1) DE602005025363D1 (en)
ES (1) ES2355733T3 (en)
MX (1) MX2007000760A (en)
TW (1) TW200621249A (en)
WO (1) WO2006014762A1 (en)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
WO2009032277A1 (en) 2007-09-06 2009-03-12 Schering Corporation Gamma secretase modulators
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2010056849A1 (en) 2008-11-13 2010-05-20 Schering Corporation Gamma secretase modulators
WO2010075204A2 (en) 2008-12-22 2010-07-01 Schering Corporation Gamma secretase modulators
WO2010075203A1 (en) 2008-12-22 2010-07-01 Schering Corporation Gamma secretase modulators
US7759354B2 (en) 2005-06-14 2010-07-20 Schering Corporation Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2010147975A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
WO2010147973A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
US7868000B2 (en) 2005-06-14 2011-01-11 Schering Corporation Aspartyl protease inhibitors
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011044181A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US8093254B2 (en) 2006-12-12 2012-01-10 Schering Corporation Aspartyl protease inhibitors
US8168641B2 (en) 2006-06-12 2012-05-01 Schering Corporation Aspartyl protease inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2013028670A1 (en) 2011-08-22 2013-02-28 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
US8426595B2 (en) 2007-12-11 2013-04-23 Xianhai Huang Gamma secretase modulators
US8487099B2 (en) 2007-11-05 2013-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
US8541427B2 (en) 2008-04-22 2013-09-24 Merck, Sharp & Dohme, Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
WO2014062549A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014062553A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase
EP3607946A1 (en) 2012-03-19 2020-02-12 Buck Institute for Research on Aging App specific bace inhibitors (asbis) and uses thereof
EP3653609A1 (en) 2013-02-12 2020-05-20 Buck Institute for Research on Aging Hydantoins that modulate bace-mediated app processing

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013036671A1 (en) * 2011-09-07 2013-03-14 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003842A1 (en) * 1987-10-21 1989-05-05 The Upjohn Company Renin inhibitors containing a (1-amino-2-hydroxy-2-heterocyclic) ethyl moiety
US20020019424A1 (en) * 2000-06-30 2002-02-14 Vincent Mutel 1-sulfonyl pyrrolidine derivatives
EP1299349A2 (en) * 2000-06-30 2003-04-09 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2003035613A2 (en) * 2001-10-22 2003-05-01 Enanta Pharmaceuticals, Inc. Nitrogen heterocycle inhibitors of aspartyl protease
US20040116414A1 (en) * 2002-05-07 2004-06-17 Tung Jay S. Succinoyl aminopyrazoles and related compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
MXPA01008606A (en) 1999-02-26 2003-05-05 Merck & Co Inc Novel sulfonamide compounds and uses thereof.
DE19934145C2 (en) * 1999-07-26 2001-05-23 Deutsche Telekom Mobil Method for establishing communication connections to a preferably mobile communication terminal device associated with a vehicle or other mobile or stationary device
PE20020276A1 (en) 2000-06-30 2002-04-06 Elan Pharm Inc SUBSTITUTE AMINE COMPOUNDS AS ß-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
AR035260A1 (en) 2001-08-03 2004-05-05 Schering Corp DERIVATIVES OF REPLACED AMINO PIPERIDINE, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF MEDICINES AS INHIBITORS OF THE SECRETASE RANGE, AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
CA2455863C (en) * 2001-08-03 2010-10-12 Schering Corporation Tetrahydroquinoline derivatives as gamma secretase inhibitors
JP3711131B2 (en) 2001-08-21 2005-10-26 メルク シャープ エンド ドーム リミテッド New cyclohexylsulfone
TW200302717A (en) 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
US20050227699A1 (en) 2002-06-26 2005-10-13 Harmen Schreuder Method and network element for optimisation of radio resource utilisation in radio access network
JP4494212B2 (en) * 2002-11-12 2010-06-30 メルク・シャープ・エンド・ドーム・コーポレイション Phenylcarboxamide beta-secretase inhibitor for the treatment of Alzheimer's disease
EP1740575A2 (en) * 2004-04-22 2007-01-10 Eli Lilly And Company Pyrrolidine derivatives useful as bace inhibitors
WO2007058862A2 (en) * 2005-11-16 2007-05-24 Merck & Co., Inc. Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003842A1 (en) * 1987-10-21 1989-05-05 The Upjohn Company Renin inhibitors containing a (1-amino-2-hydroxy-2-heterocyclic) ethyl moiety
US20020019424A1 (en) * 2000-06-30 2002-02-14 Vincent Mutel 1-sulfonyl pyrrolidine derivatives
EP1299349A2 (en) * 2000-06-30 2003-04-09 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2003035613A2 (en) * 2001-10-22 2003-05-01 Enanta Pharmaceuticals, Inc. Nitrogen heterocycle inhibitors of aspartyl protease
US20040116414A1 (en) * 2002-05-07 2004-06-17 Tung Jay S. Succinoyl aminopyrazoles and related compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
T. W. GREENE ET AL.: "Protective Groups in organic Synthesis", 1991, WILEY

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183252B2 (en) 2003-12-15 2012-05-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US8242112B2 (en) 2003-12-15 2012-08-14 Schering Corporation Heterocyclic aspartyl protease inhibitors
US8937093B2 (en) 2003-12-15 2015-01-20 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US7973067B2 (en) 2003-12-15 2011-07-05 Schering Corporation Heterocyclic aspartyl protease inhibitors
US8178513B2 (en) 2003-12-15 2012-05-15 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US9416108B2 (en) 2003-12-15 2016-08-16 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7759354B2 (en) 2005-06-14 2010-07-20 Schering Corporation Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof
US7868000B2 (en) 2005-06-14 2011-01-11 Schering Corporation Aspartyl protease inhibitors
US8629155B2 (en) 2006-06-12 2014-01-14 Merck Sharp & Dohme, Corp. Aspartyl protease inhibitors
US8168641B2 (en) 2006-06-12 2012-05-01 Schering Corporation Aspartyl protease inhibitors
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US8093254B2 (en) 2006-12-12 2012-01-10 Schering Corporation Aspartyl protease inhibitors
US8691831B2 (en) 2007-02-23 2014-04-08 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US8691833B2 (en) 2007-02-23 2014-04-08 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US8829036B2 (en) 2007-02-23 2014-09-09 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
EP2481408A2 (en) 2007-03-01 2012-08-01 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2009032277A1 (en) 2007-09-06 2009-03-12 Schering Corporation Gamma secretase modulators
US8487099B2 (en) 2007-11-05 2013-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
US8426595B2 (en) 2007-12-11 2013-04-23 Xianhai Huang Gamma secretase modulators
US8541427B2 (en) 2008-04-22 2013-09-24 Merck, Sharp & Dohme, Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
WO2010056849A1 (en) 2008-11-13 2010-05-20 Schering Corporation Gamma secretase modulators
WO2010075203A1 (en) 2008-12-22 2010-07-01 Schering Corporation Gamma secretase modulators
WO2010075204A2 (en) 2008-12-22 2010-07-01 Schering Corporation Gamma secretase modulators
WO2010147973A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
WO2010147975A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9029362B2 (en) 2009-10-08 2015-05-12 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as brace inhibitors, compositions, and their use
WO2011044181A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
US9687494B2 (en) 2009-10-08 2017-06-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9475785B2 (en) 2009-10-08 2016-10-25 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US9428475B2 (en) 2009-10-08 2016-08-30 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US8729071B2 (en) 2009-10-08 2014-05-20 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
EP3034080A1 (en) 2009-10-08 2016-06-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8940748B2 (en) 2009-10-08 2015-01-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2013028670A1 (en) 2011-08-22 2013-02-28 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
EP3607946A1 (en) 2012-03-19 2020-02-12 Buck Institute for Research on Aging App specific bace inhibitors (asbis) and uses thereof
WO2014062553A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014062549A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP3653609A1 (en) 2013-02-12 2020-05-20 Buck Institute for Research on Aging Hydantoins that modulate bace-mediated app processing
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase

Also Published As

Publication number Publication date
JP2008507538A (en) 2008-03-13
US7803802B2 (en) 2010-09-28
EP1781625B1 (en) 2010-12-15
US20060040994A1 (en) 2006-02-23
DE602005025363D1 (en) 2011-01-27
ATE491693T1 (en) 2011-01-15
CN101014577A (en) 2007-08-08
AR049726A1 (en) 2006-08-30
MX2007000760A (en) 2007-04-09
EP1781625A1 (en) 2007-05-09
US8367712B2 (en) 2013-02-05
TW200621249A (en) 2006-07-01
ES2355733T3 (en) 2011-03-30
US20110003825A1 (en) 2011-01-06
CA2574218A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
EP1781625B1 (en) Substituted amide beta secretase inhibitors
EP1781644B1 (en) Macrocyclic beta-secretase inhibitors
EP1945626B1 (en) Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
US8518975B2 (en) Gamma secretase modulators
JP2010535762A (en) Gamma secretase modulator
MX2007016183A (en) The preparation and use of compounds as protease inhibitors.
MX2010011563A (en) Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use.
EP2178857A1 (en) Gamma secretase modulators
US8673900B2 (en) Gamma secretase modulators
US8759337B2 (en) Gamma secretase modulators
EP2205567A1 (en) Gamma secretase modulators
EP2142538B1 (en) Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
US20120135980A1 (en) Gamma secretase modulators
US8809318B2 (en) Gamma secretase modulators
US7879997B2 (en) Compounds for the treatment of inflammatory disorders
US20120245158A1 (en) Gamma secretase modulators

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2574218

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/000760

Country of ref document: MX

Ref document number: 2007522711

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005773473

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580030034.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005773473

Country of ref document: EP